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INTRODUCTION 
Carcinoma of breast is the most common of non-skin malignancies in 
women and is second to lung cancer being a cause of cancer deaths. A woman 
who lives to age 90 has a one in eight chance of developing breast cancer[1]. It 
is as ironic and tragic that a neoplasm arising in an exposed organ, readily 
accessible to self-examination and clinical surveillance, continues to exact such 
a heavy toll.  
The treatment of the primary breast cancer relies primarily on surgery. 
The surgery for breast cancer dates back to first century from when various 
modification has occurred in its treatment and now being evolved into 
MODIFIED RADICAL MASTECTOMY (MRM) and Breast conservation 
surgery which are being performed increasingly over the last 2 decades, and for 
many surgeons either of these has become the "standard operation" for primary 
operable breast carcinomas.  
The number of positive axillary lymph nodes foresee prognosis and is 
important in determining adjuvant therapy in breast cancer patients. This study 
was undertaken to determine if differences in the extent of axillary node 
dissection would alter the number of reported positive nodes. And there is no 
authentic evidence that, to which subset of axillary level the interpectoral nodes 
belong and whether its dissection is essential in routine MRM or not, as this 
node dissection is a standard procedure in radical mastectomy.  
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This report is an observational study details from the Department of 
General Surgery, Govt. Stanley Medical College and Hospital, Chennai, which 
contains the results of patients undergoing MRM performed between March 
2016 to August 2017, in which the each level of axillary node and interpectoral 
nodes are submitted as a separate sample at the end of the standard MRM 
procedure for histopathology, and attempts were made to define the incidence of 
node positivity in various stage of primary breast cancer and evaluate the 
significance of interpectoral node metastases in patients with primary disease.    
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REVIEW OF HISTORY 
It is remarkable that, the written records and illustrations of carcinoma 
breast dates back to relic as the location of the organ permitted easy 
identification. Edwin Smith Surgical Papyrus, dates back to 3,000–2,500 B.C., 
and is attributable to Imhotep (the Egyptian physician-architect), which 
provides credible accounts of breast cancer. A case was suspected to be 
incurable when the disease was “cool to touch, bulging and spread all over the 
breast”[2]. In ancient Greece, for relief from breast maladies a divinity was 
incited to offer, which was evidenced by votive offerings in shape of breasts in 
Greek temples which had Asclepius, who is the god of medicine. Carcinoma 
(karkinoma), scirrhous (hard, Greek skirros) and cacoethes (malignant disease, 
Greek kakoethes) in the medical eloquence owe their origins to Hellenistic 
writings. In 400 B.C. Hippocrates’ theory of the imbalance about humours 
(blood, phlegm, and yellow and black bile) caused disease. He has described the 
progressive stages of carcinoma breast which represents early axiom about the 
cause of carcinoma[3]. 
In 1st century A.D., Leonides of Alexandria followed the traditions of 
Greek. He detailed about incision and cautery in his approach[4]. His 
requirement of leaving a wide margin of excision and only removing tumours of 
limited extent, prefigures the oncological principles of contemporary surgical 
practice. Galen, explained breast cancer in 200 A.D. as pile of black bile in the 
blood, wind up that it was a systemic disease. These ancient physicians 
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presuppose that the cessation of menstruation was linked to carcinoma; it was 
probably due to the association of carcinoma with old age. Along this theory, 
Galen made surgical wounds to bleed openly to get rid of the black bile and he 
dismayed the use of ligatures. He coined the word ‘crab’ for cancer to 
exemplify the dilated veins radiating from the tumour[5].  
But during the Middle Ages there was surgical stagnation in treatment of 
Breast cancer. From 476 to 1,500 A.D. the religious philosophies unavoidably 
intertwined medical progress. Early Christian conviction was more towards 
faith that heals and was doing marvels over surgery, which was felt as barbaric. 
Islamic evolution made meticulous translations of Greek medicine and saved 
medical knowledge. In 10th century, Avicenna and Albucasis and in 12th 
century Maimonides (Spain) were Arab physicians of fame, spread the medical 
values to all the countries which ever they conquered. Cautery in Surgery was 
strongly recommended by Albucasis in surgery[6]. They used caustic pastes to 
bring down the size of the tumor and make it operable, is the same logic for 
using chemotherapy for large breast cancers nowadays. Albucasis, Henri de 
Mondeville who is the ‘father’ of French surgery in 13th century and Guy de 
Chauliac from France, 14th century introduced unique instrument for rapid 
removal of breast tumors. 
The period of Renaissance with celebration of arts and the emergence of 
surgery, dates back for 16th to 18th centuries, was the age of artistic creativity 
and was the golden age for emergence of surgery. Andreas Vesalius in 16th 
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century in Belgium gave a strong anatomical exploration of human body 
following which refinement of surgery was done. The identification of Cooper’s 
eponymous ligaments of the breast and Sappey’s subareolar plexus of 
lymphatics in 18
th
 century in England and France made clear about the origins 
and spread of breast cancer[7,8]. In 18
th
 century, John Hunter who was called 
the Scottish ‘father’ of investigative surgery made efforts to replace the term 
‘black bile’ to lymph as the cause of breast cancer. There are many theories 
ranging from inspissated milk, trauma, personality type, exposure to air and 
infection that were mounted for carcinogenesis. The observation of the disease 
within families was naturally attributed to infection. While there was an extreme 
search for the correct treatment of Carcinoma breast surgeries like simple 
lumpectomies amounting to radical removal of the pectoralis, recreated medical 
records. These procedures were tremendously appreciated because, the absence 
of anaesthesia warranted exclusive skill and speed of the surgeon to operate. It 
is also a grim reminder that surgery was the solitary modality of hope for relief 
with anecdotal incidences of cure. Use of ligatures or lead plates to strangulate 
the tumours were the more conservative approaches, preferring them to the 
horrors of breast amputation. 
It was the Nineteenth Century, which is deemed as the golden era of 
surgery. The surgical exercise improved during this period where there were 
multiple discoveries in the supporting fields making surgery easy. The first 
landmark events were invention of Disinfection, sterilisation and use of sterile 
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gloves. Introduction of General anaesthesia revolutionised surgeon’s ease (and 
indeed the patient’s too!). In 1818 James Blundell made an attempt of blood 
transfusion for treating postpartum haemorrhage, but the safe transfusions were 
achieved only at the starting of the 20th century, when Karl Landsteiner 
discovered blood groups. Along with these discoveries, other contributions to 
cancer came from the identification of normal cells through microscope and 
their cancerous outrage all the way from Hooke in 17th century to Müller and 
Virchow in 19th century. Müller was the one who discouraged the humoral 
theory for origin of cancer, declaring that cancers were composed of living cells 
and he only suggested that metastasis was due to spread of these living cells. 
Basis of variety of excision techniques for treatment was framed after the 
demonstration of breast cancer spread through the lymphatics to corresponding 
axillary nodes. Unique forms of spread that caused the clinical appearance of 
carcinoma en cuirasse or peau d’orange and Paget’s disease made to think of 
alternative ways of approaching treatment. 
The middle years of 19th century were renowned because of the newly 
acquired surgical freedom with bold and radical surgeries. The en bloc 
resections by Charles Moore in London, and Kuster and Volkmann in Germany 
ran a parallel course[10]. In 1882, William Banks in Liverpool performed 
Axillary lymph node dissections as part of the philosophy of extermination [11]. 
It may appear particularly mutilating today, but they provided a unique 
opportunity to study the spread disease. At the turn of century Breast cancer 
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surgery came to be synonymous with the name of Sir William S. Halstead, who 
was the Professor of Surgery at John Hopkins hospital in Baltimore, USA. He 
was the one who performed first radical mastectomy which was reported in 
1894 with the emphasis on removing tissues as a single piece so as to prevent 
spread and removal of the pectoralis major muscle to prevent recurrence. This 
method became the accepted way that generations of surgeons trod with 
diligence [12]. This view of removing the tissue as a single piece is based on the 
belief that the wound will become infected once there is division of tissues 
which are invaded by the disease or lymphatic vessels containing the cancer 
cells, and because shreds or pieces of cancerous tissue may be overlooked in the 
piecemeal extirpation [13].” 
As there were strict rules for non-violation of tumour area, a preoperative 
biopsy to confirm whether the patient had a cancer or not, was needed. So 
during olden days the strength of a skilled clinical diagnosis was excellent to do 
surgery without preoperative biopsy. There was another age old practice of 
leaving the excised surgical wounds open so that it would granulate. The use of 
ligatures was not allowed for better wound healing through low infection rates. 
At Twentieth Century, the Surgery reinvented itself. The hormone 
dependency of breast cancer was first thought to be hypothetical, then as the the 
disease was more aggressive in younger women it was proved to be true. During 
1906 Beatson enlightened the era of endocrine surgery [14]—even before the 
discovery of estrogen receptors by Jensen in 1967[15] along with oopherectomy 
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and adrenalectomy (to achieve castration) which came as a standard procedure. 
These methods of surgery were gradually replaced by the use of estrogen 
receptor modulators, luteinising hormone-releasing agonists and aromatase 
inhibitors. 
Margottini and Veronesi in Milan preserved the legacy of Halsteadian 
surgery, who removed internal mammary nodes in addition to the procedure and 
extended the scope of ‘radicality’ by removing the supraclavicular and 
mediastinal nodes. However, during the period of late 19th and early 20th 
centuries there was a common thinking that: big surgeons make big incisions 
(and hence it is better to perform big surgeries). Patey and Handley from 
London and Auchincloss Jr. of New York made little changes to the procedure  
that ‘modified’ the radical mastectomy and preserved the pectoralis major.[16] 
following the inventions of radiation as means of destroying the cancer cells and 
various forms of chemotherapeutic agents were doing the same. Also the 
invention of medical castration or targeted mutated tumour receptors, insisted 
the surgeons to revise the cancer management strategies. These discoveries and 
inventions were coupled with increase in knowledge of the biological behaviour 
of breast cancer and that made everyone to rethink treatment of the Breast 
cancer. Mammography made it possible of early cancer detection of smaller 
lesions that added a new dimension to surgical management. 
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The surgical fraternity reoriented itself for the reduced morbid surgeries 
after invention and discovery of all these. Bernard Fisher, Professor of Surgery 
from the University of Pittsburgh, imposed the belief of Galen that breast cancer 
was systemic disease. This was proved by large randomised controlled clinical 
trials which includes the National Surgical Adjuvant Breast and Bowel Project 
(NSABP), which was published in 1989.[17] Veronesi from Italy and many 
others were toward the thought that the limited surgery was enough when  
complemented by adjuvants.[18]  
With all these theories and beliefs Surgery rejuvenated itself by joining 
hands with the other modalities. At the end of the 20th century breast 
conservation and breast reconstruction were combined with sentinel node 
dissection[19]. The removal of only selected ‘sentinel’ nodes (those to which 
the tumour had spread) would reduce the incidence of swollen 
lymphoedematous arm, which is a distressing manifestation of axillary lymph 
node dissections. 
When the theory of reducing the surgical burden was coming into 
existence, In 1887, Verneuil, a French surgeon transferred autologous tissue 
from the normal breast to the diseased one.[20] This method increased the novel 
ideas for variety of innovative synthetic and autologous materials that offered a 
restored shape that could match to do nature’s original creation. Natural choices 
were muscle, myocutaneous flaps, lipomas and omentum. In 1979 Holmstrom 
introduced the transverse rectus abdominis myocutaneous flap (TRAM) that has 
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stood the test of time and it has undergone several modifications during the 
process of evolution[21]. Along with the natural materials Prosthetic and 
synthetic options were brought into industry like petroleum jelly, glass balls, 
ivory, rubber, polyvinyl alcohol sponge and silicone. 
Ever since the first recorded medical literature, the surgical domination 
was over the other methods in treatment of breast cancer. But At last, surgery 
remains as the heart of management in a multimodality setting. It balances cure 
and cosmesis to breast cancer survivor by providing succour instead of 
annihilation. 
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INFERENCES FROM THE HISTORY  
The major lessons to be gained from the history of surgery are as follows.  
 First, overlooking into history is very important to rediscover the buried 
insights: Galen’s perceptive assessment was, breast cancer is a systemic 
disease which was rediscovered after two millennia later in 20th century 
by Fisher’s observations.  
 Second, the evolution of therapeutic methods has increased the fortunes 
of medical disciplines (like antisepsis and anaesthesia did for surgery) 
and has minimised their supremacy as stand-alone choices for treatment 
or cure.  
 Third, adaptation is the best method for survival in contemporary medical 
practice. Surgery has won the day by adapting and playing a 
complementary role in modern cancer management as a patient-friendly, 
scientific and stylised craft. 
 Finally any procedure by oncological principle needs complete removal 
of the cancer affected tissues that needs radicality of removing the 
affected tissues. 
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ANATOMY 
The breasts form the secondary sexual feature of females and are the 
source of nutrition for neonate. They are present in a rudimentary form in 
males. The breasts are the site of malignant change in as many as one in ten 
women. In young adult females, each breast is a rounded eminence that lies 
within the superficial fascia, largely anterior to upper thorax but spreading 
laterally to a variable extent. Breast shape and size depends upon genetic, racial 
and dietary factors, and the age, parity and menopausal status of individual. 
Breasts may be hemispherical, conical, variably pendulous, piriform or thin and 
flattened. In an adult female, the base of the breast, i.e. its attached surface, 
extends vertically from the second or third to the sixth rib, and in transverse 
plane from the sternal edge medially almost to the mid axillary line laterally. 
The superolateral quadrant is prolonged towards the axilla along the 
inferolateral edge of pectoralis major, from where it projects a little, and may 
extend through the deep fascia up to apex of the axilla (the axillary tail of 
Spence)[22].  
The trunk superficial fascial system splits and encloses the breast to form 
the anterior and posterior lamellae. Posterior extensions of superficial fascial 
system connect the breast to the pectoralis fascia, which is a part of the deep 
fascial system. The inframammary crease is a zone of adherence of the 
superficial fascial system to the underlying chest wall at the inferior crescent of 
the breast. The breast lies upon the deep pectoral fascia, which in turn overlies 
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pectoralis major and serratus anterior superiorly and external oblique and its 
aponeurosis (the latter forms the anterior wall of the sheath of rectus abdominis) 
inferiorly. Between the breast and the deep fascia the loose connective tissue in 
the ‘submammary space’ allows the breast for some degree of movement on the 
deep pectoral fascia. Advanced mammary carcinoma may, by invasion, cause 
tethering or fixation of breast to the underlying musculature.  
Occasionally, small projections of glandular tissue may pass through the 
deep fascia into the underlying muscle in normal subjects. The nipple projects 
from centre of the breast anteriorly. Its shape and projection varies from 
cylindrical to round at the top, to hemispherical, to flattened, depending on 
nervous, hormonal, developmental and other factors. The level of the nipple 
varies widely from person to person. In females, its site is dependent on the size 
and shape of the breasts, but it overlies the fourth intercostal space in most 
young women. In the male, the nipple is usually sited in the fourth intercostal 
space in the midclavicular line. In the young adult of the either sex, the nipples 
are usually positioned 20–23 cm from the suprasternal notch in the 
midclavicular line and 20–23 cm apart in the horizontal plane. With increasing 
age and parity, female breasts adopt a more ptotic shape and the nipple position 
drops either to the level of the inframammary crease or it lies below this surface 
landmark. In the nulliparous, it is pink, light brown or darker, depending on the 
general melanisation of the body. Occasionally, the nipple may not evert during 
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prenatal development, in which case it remains permanently retracted and so it 
causes difficulty in suckling. 
 
 
 
NIPPLE AND AREOLA 
The skin that covers the nipple and the surrounding areola (the disc of 
skin that circles the base of the nipple) has a convoluted surface. It contains 
numerous sweat and sebaceous glands which open directly onto the skin 
surface. The oily secretion from these specialized sebaceous glands acts as a 
protective lubricant and facilitates latching of the neonate during lactation: these 
glands are often visible in parous women, arranged circumferentially as small 
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elevations, Montgomery’s tubercles, around the areola close to the margin. 
Other areolar glands, which are intermediate in structure between mammary and 
sweat glands, become enlarged in pregnancy and lactation as subcutaneous 
tubercles. The sebaceous glands of the areola usually lack hair follicles. The 
skin of the nipple and areola is rich in melanocytes and is therefore typically 
darker than the skin covering the remainder of the breast: further darkening 
occurs during the second month of pregnancy, which subsequently persists to a 
variable degree. 
                                       
 
SOFT TISSUE 
The breast is composed of lobes which contain a network of glandular 
tissue consisting of branching ducts and terminal secretory lobules in a 
connective tissue stroma. The terminal duct lobular unit is the functional unit 
which is the milk secretory component of the breast and pathologically gives 
rise to primary malignant lesions within the breast. Although the lobes are 
usually described as discrete territories, they intertwine in three dimensions and 
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merge at their edges, which cannot be distinguished during surgery. The 
connective tissue stroma that surrounds the lobules is dense and 
fibrocollagenous, whereas intralobular connective tissue has a loose texture that 
allows rapid expansion of secretory tissue during pregnancy. Fibrous strands or 
the sheets consisting of condensations of connective tissue extend between the 
layer of deep fascia that covers the muscles of the anterior chest wall and the 
dermis. These suspensory ligaments (of Astley Cooper) are often well 
developed in the upper part of the breast that supports the breast tissue and helps 
to maintain its non-ptotic form. Elsewhere in the normal breast, fibrous tissue 
surrounds the glandular components and extends to the skin and nipple which 
assists the mechanical coherence of the gland. The interlobar stroma contains 
variable amounts of adipose tissue that is responsible for much of the increase 
in breast size at puberty 
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VASCULAR SUPPLY  
Arteries 
The breasts are supplied by branches of the axillary artery, the internal 
thoracic artery, and some intercostal arteries. The axillary artery supplies blood 
through the superior thoracic artery, the pectoral branches of the 
thoracoacromial artery, the lateral thoracic artery (through the branches which 
curve around the lateral border of pectoralis major that supplies the lateral 
aspect of the breast) and the subscapular artery. The internal thoracic artery 
supplies perforating branches to anteromedial part of the breast. The second to 
fourth anterior intercostal arteries supply perforating branches more laterally in 
anterior thorax of which the second perforating artery is usually the largest, and 
supplies the upper region of the breast, and the nipple, areola and adjacent 
breast tissue. 
 
Veins 
Blood drains from the circular venous plexus around the areola and from 
the glandular tissue of the breast into the axillary, internal thoracic and 
intercostal veins via veins that accompany the corresponding arteries. Individual 
variation is common in venous drainage. 
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Innervation 
The breast is innervated by anterior and lateral branches of fourth to sixth 
intercostal nerves, which carry sensory and sympathetic efferent fibres. The 
nipple is supplied from the anterior branch of lateral cutaneous branch of T4 
which forms an extensive plexus in the nipple; its sensory fibres terminate close 
to the epithelium as free endings, Meissner corpuscles and Merkel disc endings. 
These are essential in signalling pathway during suckling to the central nervous 
system. Secretory activities of the gland are largely controlled by ovarian and 
the hypophysial hormones rather than by the efferent motor fibres. The areola 
has fewer sensory endings. 
 
TERMINAL DUCT LOBULAR COMPLEX 
Each breast, contains 15-20 lobes and each lobe is comprised of 20-40 
terminal ductal lobular units (TDLU). The TDLU is the functional unit of the 
breast. TDLUs consists of: Extralobar terminal duct (ETD) which attaches the 
lobule to the ductal system, Intralobar terminal duct (ITD) that continues the 
duct system into the lobule clusters of 10-100 sac-like acini that open into the 
ITD, and the Acini which are the source of milk production. "The epithelium 
throughout the ductal-lobular system is bilayered, consisting of an inner 
(luminal) epithelial cell layer and an outer (basal) myoepithelial cell layer" as 
described above. 
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Visual, auditory and areola stimulation trigger a neuroendocrine reflex 
which releases oxytocin from the posterior pituitary. Oxytocin travels in the 
blood to the mammary gland where it stimulates specific receptors on 
myoepithelial cells, causing them to contract and expel milk into the ducts and 
on toward the nipple. Each lobe empties into a lactiferous duct. Lactiferous 
ducts merge into 5-10 main lactiferous ducts that open at the nipple. The 
majority of pathologic changes in the breast, including DCIS and invasive 
carcinomas, are believed to arise from the TDLU. 
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MICROSTRUCTURE 
The microstructure of breast tissue varies with the age, time in the 
menstrual cycle, pregnancy and lactation. The following description relates to 
mature, resting breast. For most of their lengths, the ducts are usually lined by 
columnar epithelium. In case of larger ducts, this is two cells thick, but, in the 
smaller ones, it is only a single layer of columnar or cuboidal cells. The bases of 
these cells are in close contact with numerous myoepithelial cells which are 
ectodermal in origin, similar to those of certain other glandular epithelia. 
Myoepithelial cells are so numerous that they form a distinct layer around the 
ducts and the presumptive alveoli and give the epithelium a bilayered 
appearance.  
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DEVELOPMENT 
The epithelial/mesenchymal interactions gives rise to the glandular tissue 
of the breast, in both sexes, which can first be seen at about the fifth or sixth 
week, when two ventral bands of thickened ectoderm, the mammary ridges or 
milk lines, extend from the axilla to inguinal region. Usually, invagination of 
the thoracic mammary bud occurs by day 49, and the remaining mammary line 
involutes. The thoracic ectodermal ingrowths branch into 15–20 solid buds of 
ectoderm that will become the lactiferous ducts and their associated lobes of 
alveoli in the fully formed gland. They are surrounded by somatopleuric 
mesenchyme that forms the connective tissue, fat and vasculature which is 
invaded by the mammary nerves. Continued cell proliferation, elongation and 
further branching produce the alveoli and define the duct system. Nipple 
formation begins at day 56, primitive ducts (mammary sprouts) develop at 84 
days and canalization occurs at about the 150th day. During the last 2 months of 
gestation the ducts become canalized; the epidermis at the point of original 
development of the gland forms a small mammary pit, into which the lactiferous 
tubules open. Perinatally the nipple is formed by mesenchymal proliferation. 
Should this process fail, the ducts open into shallow pits. Rarely, the nipple may 
not develop (athelia), a phenomenon that occurs more commonly in accessory 
breast tissue.[22]  
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At birth the breasts have reached a similar developmental stage in both 
sexes: the combination of fetal prolactin and the maternal oestrogen which may 
give rise to transient hyperplasia and secretion of ‘witch’s milk’. In males, the 
breasts normally remain undeveloped, whereas in females at puberty, in late 
pregnancy and during the period of lactation, they undergo further, hormone-
dependent, developmental changes. The female breast is a unique organ and it 
remains in a rudimentary (i.e. fetal) form until puberty, at which time its 
development continues under the influence of sex hormones. The adult form is 
reached in late adolescence, i.e. the breast is then able to function as a milk-
producing organ. At the time of menopause, the breast involutes into a 
predominantly fatty organ with minimal glandular parenchyma.  
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CONTROVERSIES IN LITERATURE REGARDING LYMPHATICS 
On looking back into the literatures, the standard texts sometimes fail to 
define the levels of axillary nodes. The levels have been designated mainly 
based on the fact that the lymph flow from breast form a chain of contiguous 
spread and so it may be used to prognosticate the disease morbidity if correctly 
analysed. Let us see some of the discrepancies in the description of anatomy  
Gray's anatomy – the anatomical basis of clinical practice 40th edition 
states that, “The breast lymphatics branch extensively and do not contain 
valves: lymphatic blockage through tumour occlusion may therefore result in 
reverse blood flow through the lymphatic channels. The direction of lymphatic 
flow within the breast parallels major venous tributaries and enters the regional 
lymph nodes through the extensive periductal and perilobular network of 
lymphatic channels. Most of these lymphatics drain into axillary group of 
regional lymph nodes either directly or through the retroareolar lymphatic 
plexus. Dermal lymphatics also penetrate pectoralis major to join these channels 
that drain the deeper parenchymal tissues, and follow the vascular channels to 
terminate in the subclavicular lymph nodes.  
Lymphatics from the left breast ultimately terminate in the thoracic duct 
and subsequently the left subclavian vein. On the right, the lymphatics 
ultimately drain into the right subclavian vein near its junction with the internal 
jugular vein. Part of medial side of the right breast drains towards the internal 
thoracic group of lymph nodes. The internal thoracic chain may drain inferiorly 
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via the superior and inferior epigastric lymphatic routes to the groin. Connecting 
lymphatics across the midline may provide access of lymphatic flow to the 
opposite axilla. Axillary nodes receive more than 75% of the lymph from the 
breast. There are 20–40 nodes, grouped artificially as pectoral (anterior), 
subscapular (posterior), central and apical. Surgically, these nodes are described 
in relation to pectoralis minor[23]. 
Those lying below pectoralis minor are the low nodes (level 1), those 
behind the muscle are the middle group (level 2), while the nodes between the 
upper border of pectoralis minor and the lower border of the clavicle are the 
upper or apical nodes (level 3). There may be one or two other nodes between 
pectoralis minor and major; this interpectoral group of nodes are also known as 
Rotter’s nodes[25].  
Efferent vessels directly from the breast pass round the anterior axillary 
border through the axillary fascia to the pectoral lymph nodes; some may pass 
directly to the subscapular nodes. A few vessels pass from the superior part of 
the breast to the apical axillary nodes, sometimes interrupted by the 
infraclavicular nodes or by small, inconstant, interpectoral nodes. Most of the 
remainder drains to parasternal nodes from the medial and lateral parts of the 
breast; they accompany perforating branches of the internal thoracic artery. 
Lymphatic vessels occasionally follow lateral cutaneous branches of the 
posterior intercostal arteries to the intercostal nodes.” 
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However MOORE - CLINICALLY ORIENTED ANATOMY 7
TH
 ED 
does not include interpectoral nodes in axillary group as it says “The lymphatic 
drainage of the breast is important because of its role in the metastasis of cancer 
cells. Lymph passes from the nipple, areola, and lobules of the gland to the 
subareolar lymphatic plexus. From this plexus: Most lymph (>75%), especially 
from the lateral breast quadrants, drains to the axillary lymph nodes, initially to 
the anterior or pectoral nodes for the most part. However, some lymph may 
drain directly to other axillary nodes or even to interpectoral, deltopectoral, 
supraclavicular, or inferior deep cervical nodes.” 
 
While LAST’S ANATOMY 12th EDITION says “some lymph from the 
breast may drain into one or two infraclavicular nodes in the deltopectoral 
groove or into small inconstant interpectoral nodes between pectoralis major 
and minor. 
 
Schwartzs - principles of surgery, 10
th
  edition describes, “The boundaries 
for lymph drainage of the axilla are not well demarcated. The six axillary lymph 
node groups recognized by surgeons are:  
(a) The axillary vein group (lateral), which consists of four to six lymph nodes 
that lie medial or posterior to the vein and receive most of the lymph drainage 
from the upper extremity;  
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(b) the external mammary group (anterior or pectoral group), which consists of 
five to six lymph nodes that lie along the lower border of the pectoralis minor 
muscle contiguous with the lateral thoracic vessels and receive most of the 
lymph drainage from the lateral aspect of the breast;  
(c) the scapular group (posterior or subscapular), which consists of five to seven 
lymph nodes that lie along the posterior wall of the axilla at the lateral border of 
the scapula contiguous with the subscapular vessels and receive lymph drainage 
principally from the lower posterior neck, the posterior trunk, and the posterior 
shoulder;  
(d) the central group, which consists of three or four sets of lymph nodes that 
are embedded in the fat of the axilla lying immediately posterior to the 
pectoralis minor muscle and receive lymph drainage both from the axillary vein, 
external mammary, and scapular groups of lymph nodes, and directly from the 
breast;  
(e) the subclavicular group (apical), which consists of six to twelve sets of 
lymph nodes that lie posterior and superior to the upper border of the pectoralis 
minor muscle and receive lymph drainage from all of the other groups of 
axillary lymph nodes; and  
(f) the interpectoral group (Rotter’s lymph nodes), which consists of one to four 
lymph nodes that are interposed between the pectoralis major and pectoralis 
minor muscles and receive lymph drainage directly from the breast. The lymph 
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fluid that passes through the interpectoral group of lymph nodes passes directly 
into the central and subclavicular groups.  
The lymph node groups are assigned levels according to their anatomic 
relationship to the pectoralis minor muscle.  
 Lymph nodes located lateral to or below the lower border of the 
pectoralis minor muscle are referred to as level I lymph nodes, which 
include the axillary vein, external mammary, and scapular groups.  
 Lymph nodes located superficial or deep to the pectoralis minor muscle 
are referred to as level II lymph nodes, which include the central and 
interpectoral groups.  
 Lymph nodes located medial to or above the upper border of the 
pectoralis minor muscle are referred to as level III lymph nodes, which 
consist of the subclavicular group.  
The plexus of lymph vessels in the breast arises in the interlobular 
connective tissue and in the walls of the lactiferous ducts and communicates 
with the subareolar plexus of lymph vessels. Efferent lymph vessels from the 
breast pass around the lateral edge of the pectoralis major muscle and pierce the 
clavipectoral fascia, ending in the external mammary (anterior, pectoral) group 
of lymph nodes. Some lymph vessels may travel directly to the subscapular 
(posterior, scapular) group of lymph nodes. From the upper part of the breast, a 
few lymph vessels pass directly to the subclavicular (apical) group of lymph 
nodes.  
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The axillary lymph nodes usually receive >75% of the lymph drainage 
from the breast. The rest is derived primarily from the medial aspect of the 
breast, flows through the lymph vessels that accompany the perforating 
branches of the internal mammary artery, and enters the parasternal (internal 
mammary) group of lymph nodes.” 
 
 
 
 
 
 
 
 
 
Sabiston textbook of surgery - the biological basis of modern surgical 
practice, 20e says “Level I nodes are located lateral to the lateral border of the 
pectoralis minor muscle. Level II nodes are located posterior to the pectoralis 
minor muscle. Level III nodes are located medial to the pectoralis minor muscle 
and include the subclavicular nodes. Level III nodes are easier to visualize and 
remove when the pectoralis minor muscle is divided. The apex of the axilla is 
defied by the costoclavicular ligament (Halsted’s ligament), at which point the 
axillary vein passes into the thorax and becomes the subclavian vein. Lymph 
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nodes in the space between the pectoralis major and minor muscles are termed 
the interpectoral group or Rotter’s nodes, as described by Grossman and Rotter. 
Unless these nodes are specifically exposed, they are not encompassed in 
surgical procedures that preserve the pectoral muscles.” Here the author does 
not include the rotters node in any level of axillary nodes. 
 
 
DEVITA, HELLMAN & ROSENBERG'S CANCER - PRINCIPLES AND 
PRACTICE OF ONCOLOGY 9TH ED 
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FISCHER'S MASTERY OF SURGERY 6E says “Axillary lymphatics 
are also divided according to their lateral and medial (surgical) anatomic 
relationships with the pectoralis minor muscle into three distinct levels and are 
identified as levels I through III.  
 Level I nodes are located lateral to or below the inferior border of the 
pectoralis minor; this level includes the extremal mammary, the lateral 
axillary vein and the scapular lymph node groups.  
 Level II nodes are located deep in or behind the pectoralis minor and 
include the central lymph node group and possibly some of the 
subclavicular lymph node group.  
 Level III nodes are located superomedial to the upper margin of the 
pectoralis minor and include the subclavicular (apical) lymph node group. 
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WASHINGTON MANUAL OF SURGERY - 6E describes as “The 
borders of the axilla are defined as the axillary vein superiorly, latissimus dorsi 
laterally, and the serratus anterior muscle medially. 
 A. Axillary lymph nodes are classified according to their anatomic location 
relative to the pectoralis minor muscle. 
 1. Level I nodes. Lateral to the pectoralis minor muscle. 
 2. Level II nodes. Posterior to the pectoralis minor muscle. 
 3. Level III nodes. Medial to the pectoralis minor muscle and most accessible 
with division of the muscle. 
 4. Rotter’s nodes. Between the pectoralis major and the minor muscles.” 
 Thus there are various controversies in assigning the level of lymph node 
groups by various authors which elicits the need of interpectoral node dissection 
in proposed surgery.   
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AIMS AND OBJECTIVE 
1. To determine, if differences in the extent of axillary node dissection 
would alter the number of reported positive nodes. 
2. To examine the pattern of lymph node metastases in the axilla, and 
evaluate the merits of a level III axillary dissection. 
3. To emphasize the presence and importance of dissecting the interpectoral 
node (Rotter’s Node) in Modified Radical Mastectomy. 
MATERIALS AND METHODS 
SOURCE OF DATA: 
 This study is conducted in the Department of General Surgery, 
Government Stanley Medical College, Chennai. 
PERIOD OF STUDY:  
 March 2016 to Aug 2017 (18 months) 
INCLUSION CRITERIA: 
 Patients with primary breast cancer whose clinical stage of Stage I, II A, 
II B and IIIA (staged as per NCCN guidelines) were included. 
EXCLUSION CRITERIA 
 Patients undergoing Breast conservation surgery 
 Patients who received Neoadjuvant chemotherapy for Stage III A 
 Stage III B and IV 
 Metastatic Carcinoma breast. 
 Recurrent Carcinoma Breast 
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METHODOLOGY 
 Patients were evaluated according to NCCN guidelines and were 
subjected to Modified Radical Mastectomy for whomsoever it was 
needed. 
 32 cases underwent Modified Radical Mastectomy with complete axillary 
dissection (level I/II/III and interpectoral node) according to identical 
procedure. The dissection was carried out in all patients, irrespective of 
whether they had palpable nodes or not clinically. 
 Level I/II, Level III and interpectoral lymph nodes were sent separately 
for routine pathological examination. 
 Observations were tabulated according to the pre-designed proforma.   
 The results are analyzed using Microsoft Excel for tabular transformation 
and graphical representation. 
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INVASIVE BREAST CARCINOMA 
Invasive breast cancers have been described as lobular or ductal in origin. 
Early classifications used the term lobular to describe invasive cancers that were 
associated with LCIS, whereas all other invasive cancers were referred to as 
ductal[28-31]. Current histologic classifications recognize special types of 
breast cancers (10% of total cases), which are defined by specific histologic 
features.[23] To qualify as a special-type cancer, at least 90% of the cancer must 
contain the defining histologic features. About 80% of invasive breast cancers 
are described as invasive ductal carcinoma of no special type (NST). These 
cancers generally have a worse prognosis than special-type cancers. Foote and 
Stewart originally proposed the following classification for invasive breast 
cancer[32]: 
1. Paget’s disease of the nipple 
2. Invasive ductal carcinoma—Adenocarcinoma with productive fibrosis 
(scirrhous, simplex, NST), 80% 
3. Medullary carcinoma, 4% 
4. Mucinous (colloid) carcinoma, 2% 
5. Papillary carcinoma, 2% 
6. Tubular carcinoma, 2% 
7. Invasive lobular carcinoma, 10% 
8. Rare cancers (adenoid cystic, squamous cell, apocrine) 
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Paget’s disease of the nipple was described in 1874. It frequently presents as 
a chronic, eczematous eruption of the nipple, which may be subtle but may 
progress to an ulcerated, weeping lesion. Paget’s disease usually is associated 
with extensive DCIS and may be associated with an invasive cancer. A palpable 
mass may or may not be present. A nipple biopsy specimen will show a 
population of cells that are identical to the underlying DCIS cells (pagetoid 
features or pagetoid change). Pathognomonic of this cancer is the presence of 
large, pale, vacuolated cells (Paget cells) in the rete pegs of the epithelium. 
Paget’s disease may be confused with superficial spreading melanoma. 
Differentiation from pagetoid intraepithelial melanoma is based on the presence 
of S-100 antigen immunostaining in melanoma and carcinoembryonic antigen 
immunostaining in Paget’s disease. Surgical therapy for Paget’s disease may 
involve lumpectomy or mastectomy, depending on the extent of involvement of 
the nipple-areolar complex and the presence of DCIS or invasive cancer in the 
underlying breast parenchyma.  
Invasive ductal carcinoma of the breast with productive fibrosis (scirrhous, 
simplex, NST) accounts for 80% of breast cancers and presents with 
macroscopic or microscopic axillary lymph node metastases in up to 25% of 
screen-detected cases and up to 60% of symptomatic cases. This cancer occurs 
most frequently in perimenopausal or postmenopausal women in the fifth to 
sixth decades of life as a solitary, firm mass. It has poorly defined margins and 
its cut surfaces show a central stellate configuration with chalky white or yellow 
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streaks extending into surrounding breast tissues. The cancer cells often are 
arranged in small clusters, and there is a broad spectrum of histologic types with 
variable cellular and nuclear grades. In a large patient series from the SEER 
database, 75% of ductal cancers showed estrogen receptor expression[33].  
Medullary carcinoma is a special-type breast cancer; it accounts for 4% of all 
invasive breast cancers and is a frequent phenotype of BRCA1 hereditary breast 
cancer. Grossly, the cancer is soft and hemorrhagic. A rapid increase in size 
may occur secondary to necrosis and hemorrhage. On physical examination, it 
is bulky and often positioned deep within the breast. Bilaterality is reported in 
20% of cases.  
Medullary carcinoma is characterized microscopically by:  
(a) a dense lympho reticular infiltrate composed predominantly of 
lymphocytes and plasma cells; 
(b) large pleomorphic nuclei that are poorly differentiated and show active 
mitosis;  
(c) a sheet-like growth pattern with minimal or absent ductal or alveolar 
differentiation.  
Approximately 50% of these cancers are associated with DCIS, which 
characteristically is present at the periphery of the cancer, and <10% 
demonstrate hormone receptors. In rare circumstances, mesenchymal metaplasia 
or anaplasia is noted. Because of the intense lymphocyte response associated 
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with the cancer, benign or hyperplastic enlargement of the lymph nodes of the 
axilla may contribute to erroneous clinical staging.  
Women with this cancer have a better 5-year survival rate than those with 
NST or invasive lobular carcinoma. Mucinous carcinoma (colloid carcinoma), 
another special type breast cancer, accounts for 2% of all invasive breast 
cancers and typically presents in the elderly population as a bulky tumor. This 
cancer is defined by extracellular pools of mucin, which surround aggregates of 
low-grade cancer cells. The cut surface of this cancer is glistening and 
gelatinous in quality. Fibrosis is variable, and when abundant it imparts a firm 
consistency to the cancer. Over 90% of mucinous carcinomas display hormone 
receptors. Lymph node metastases occur in 33% of cases, and 5- and 10-year 
survival rates are 73% and 59%, respectively. Because of the mucinous 
component, cancer cells may not be evident in all microscopic sections, and 
analysis of multiple sections is essential to confirm the diagnosis of a mucinous 
carcinoma.  
Papillary carcinoma is a special-type cancer of the breast that accounts for 
2% of all invasive breast cancers. It generally presents in the seventh decade of 
life and occurs in a disproportionate number of non white women. Typically, 
papillary carcinomas are small and rarely attain a size of 3 cm in diameter. 
These cancers are defined by papillae with fibrovascular stalks and multilayered 
epithelium. In a large series from the SEER database 87% of papillary cancers 
have been reported to express estrogen receptor. McDivitt and colleagues noted 
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that these tumors showed a low frequency of axillary lymph node metastases 
and had 5- and 10-year survival rates similar to those for mucinous and tubular 
carcinoma[34].  
Tubular carcinoma is another special-type breast cancer and accounts for 2% 
of all invasive breast cancers. It is reported in as many as 20% of women whose 
cancers are diagnosed by mammographic screening and usually is diagnosed in 
the perimenopausal or early menopausal periods. Under low-power 
magnification, a haphazard array of small, randomly arranged tubular elements 
is seen. In a large SEER database 94% of tubular cancers were reported to 
express estrogen receptor. Approximately 10% of women with tubular 
carcinoma or with invasive cribriform carcinoma, a special-type cancer closely 
related to tubular carcinoma, will develop axillary lymph node metastases. 
However, the presence of metastatic disease in one or two axillary lymph nodes 
does not adversely affect survival. Distant metastases are rare in tubular 
carcinoma and invasive cribriform carcinoma[35]. Long-term survival 
approaches 100%. Invasive lobular carcinoma accounts for 10% of breast 
cancers. The histopathologic features of this cancer include small cells with 
rounded nuclei, inconspicuous nucleoli, and scant cytoplasm. Special stains may 
confirm the presence of intracytoplasmic mucin, which may displace the 
nucleus (signet-ring cell carcinoma). At presentation, invasive lobular 
carcinoma varies from clinically inapparent carcinomas to those that replace the 
entire breast with a poorly defined mass. It is frequently multifocal, 
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multicentric, and bilateral. Because of its insidious growth pattern and subtle 
mammographic features, invasive lobular carcinoma may be difficult to detect. 
Over 90% of lobular cancers express estrogen receptor. 
Axillary Lymph Node Metastases.  
As the size of the primary breast cancer increases, some cancer cells are 
shed into cellular spaces and transported via the lymphatic network of the breast 
to the regional lymph nodes, especially the axillary lymph nodes. Lymph nodes 
that contain metastatic cancer are at first ill-defined and soft but become firm or 
hard with continued growth of the metastatic cancer. Eventually the lymph 
nodes adhere to each other and form a conglomerate mass. Cancer cells may 
grow through the lymph node capsule and fix to contiguous structures in the 
axilla, including the chest wall.[37] Typically, axillary lymph nodes are 
involved sequentially from the low (level I) to the central (level II) to the apical 
(level III) lymph node groups.  
Approximately 95% of the women who die of breast cancer have distant 
metastases, and traditionally the most important prognostic correlate of disease-
free and overall survival was axillary lymph node status. Women with node-
negative disease had less than a 30% risk of recurrence, compared with as much 
as a 75% risk for women with node-positive disease. 
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Distant Metastases.  
At approximately the twentieth cell doubling, breast cancers acquire their 
own blood supply (neovascularization). Thereafter, cancer cells may be shed 
directly into the systemic venous blood to seed the pulmonary circulation via 
the axillary and intercostal veins or the vertebral column via Batson’s plexus of 
veins, which courses the length of the vertebral column. These cells are 
scavenged by natural killer lymphocytes and macrophages. Successful 
implantation of metastatic foci from breast cancer predictably occurs after the 
primary cancer exceeds 0.5 cm in diameter, which corresponds to the twenty-
seventh cell doubling. For 10 years after initial treatment, distant metastases are 
the most common cause of death in breast cancer patients. For this reason, 
conclusive results cannot be derived from breast cancer trials until at least 5 to 
10 years have elapsed. Although 60% of the women who develop distant 
metastases will do so within 60 months of treatment, metastases may become 
evident as late as 20 to 30 years after treatment of the primary cancer.118 
Patients with estrogen receptor negative breast cancers are proportionately more 
likely to develop immunohistochemical score (IHC4) and two gene expression 
profile tests (Recurrence Score and PAM50).120 Common sites of involvement, 
in order of frequency, are bone, lung, pleura, soft tissues, and liver. Brain 
metastases are less frequent overall although with the advent of adjuvant 
systemic therapies it has been reported that CNS disease may be seen earlier. 
There are also reports of factors which are associated with the risk of 
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developing brain metastases. For example, they are more likely to be seen in 
patients with triple receptor negative breast cancer (ER-negative, PR-negative 
and HER2-negative) or patients with HER2-positive breast cancer who have 
received chemotherapy and HER2-directed therapies.[39-41] 
 
WORK UP 
For INVASIVE BREAST CANCER of stage I, II a, II b, or III a (T3, N1, 
M0) The recommended workup includes: history and physical exam; bilateral 
diagnostic mammography; breast ultrasonography, if necessary; determination 
of tumor hormone receptor status(ER and PR determinations); determination of 
HER-2 receptor status; and pathology review. Complete blood count (CBC) and 
liver function tests (LFTs) have no added benefit in the detection of underlying 
metastatic disease in asymptomatic early-stage breast cancer patients. In 
addition, monitoring of disease relapse with any tumor markers is not 
recommended. 
Use of MRI is optional and is not universally recommended by experts in 
the field. Breast MRI advocates note its high sensitivity for evaluation of extent 
of disease, particularly for invasive cancer and in dense breasts where 
mammographically occult disease is more likely to elude preoperative detection. 
MRI detractors note that MRI has a high percentage of false-positive findings 
resulting in further diagnostic workup in many circumstances including MRI-
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guided biopsy. MRI findings tend to overestimate extent of disease resulting in 
increase in frequency of mastectomies. 
MRI findings alone are insufficient to determine whether breast 
conservation therapy is optimal as additional tissue sampling is needed to verify 
true malignant disease warranting excision. MRI use may increase mastectomy 
rates by identifying  mammographically occult disease satellites that would 
have been adequately treated with post-lumpectomy radiation had the disease 
remained undiscovered without MRI.[52] 
Two prospective randomized studies have examined the utility of 
preoperative MRI in determining disease extent, and neither demonstrated 
improvement in rates of post-lumpectomy re-excision. Retrospective review of 
utility MRI showed conflicting outcome results, one with benefit and another 
without. One systematic review documented that breast MRI staging altered 
surgical treatment in 7.8% to 33.3% of women, however no differences in local 
recurrence or survival have yet been demonstrated. In addition, there  is no 
evidence that use of breast MRI increases rates of margin-negative resection. 
If breast MRI imaging is performed, a dedicated breast coil, an imaging team 
experienced with breast MRI guided biopsy, and multidisciplinary treatment 
team are the standard of care. Clinically positive axillary nodes and occult 
primary breast cancer or paget’s disease of the nipple with breast primary not 
identified on mammography, ultrasound, or physical examination are specific 
indications for breast MRI imaging. MRI may also be useful for the evaluation 
43 
 
of breast cancer response to preoperative systemic therapy and to assess the 
potential for breast-conserving therapy.[42] 
PATHOLOGY ASSESSMENT 
Full knowledge of extent of disease and biologic features is central to the 
treatment of breast cancer. Several factors contribute to the determination of the 
disease staging, recurrence risk assessment, and predictive response 
(ie,ER,PR,HER2).the excised tissue detailing the written pathology report 
details these key factors. The accuracy of pathology reporting requires 
communication between the clinician and the pathologist relating pertinent 
patient history, prior  breast biopsies, prior chest irradiation, pregnancy status, 
biopsy characteristics (i.e., palpable, mammographically detected 
microcalcifications), clinical state of lymph nodes, presence of inflammatory 
change or other skin abnormality, and prior treatment administered (i.e., 
chemotherapy, radiation therapy). 
The specimens should be oriented for the pathologist, and specific 
requests for determination of biomarkers should be stated (e.g., ER, PR, and 
HER2 status). Data from both national and local surveys show that as many as 
50% of pathology reports for breast cancer are missing some elements critical to 
patient management. Significant omissions include failure to orient and report 
surgical margins and failure to report tumor grade consistently. CAP has 
developed pathology reporting  protocols to promote complete and standardized 
reporting of malignant specimens. The NCCN breast cancer panel endorses the 
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use of the CAP protocols for reporting the pathologic analysis of all breast 
cancer specimens. 
Genetic counselling:  
For patients considered to be at high risk for hereditary breast cancer as 
defined by the NCCN Guidelines for Genetic/Familial High Risk Assessment 
Breast and ovarian, genetic counselling is recommended 
Distress assessment:  
Levels of distress may vary in patients and should be addressed 
individually. Psychological distress can be impacted by body image and other 
factors. Younger women have higher rates of psychological distress than 
women diagnosed at older ages. The NCCN Breast cancer panel recommends 
accessing for distress in patients newly diagnosed with breast cancer. 
Fertility counselling:  
Numerous epidemiologic studies have demonstrated that child-bearing 
after treatment for invasive breast cancer does not increase rates of recurrence 
or death from breast cancer. The offspring of pregnancies after treatment for 
breast cancer do not have an increased rate of birth defects or other serious 
childhood illness. However, treatment of breast cancer, especially with 
cytotoxic agents, may impair fertility. 
Many women, especially those younger than age 35, regain menstrual 
function within two years of completing chemotherapy. Resumption of menses 
does not necessarily correlate with fertility, and fertility may be preserved 
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without menses. All premenopausal patients should be informed about the 
potential impact of chemotherapy on fertility and asked about their desire for 
potential future pregnancies  
A decision for fertility preservation should include multiple factors such 
as patient preference, tumor stage and biology, age of the patient, risk of 
premature ovarian failure based on anticipated type and duration of 
chemotherapy and/or endocrine therapy, as well as the timing and duration 
allowed for fertility preservation. 
Several studies report lower rates of fertility discussion among female 
patients with cancer despite the updated ASCO guidelines stating that patients 
should not be excluded from consideration for discussion of fertility 
preservation for any reason, including parity, prognosis, age, and 
socioeconomic status. The NCCN panel recommends that all women of 
childbearing potential should have a discussion with their treating physicians. 
Patient who desire to bear children after systemic therapy should be referred to 
a fertility specialist prior to initiating systemic (chemotherapy and endocrine) 
therapy. 
Randomized trials have demonstrated that GnRH agonists (such as 
goserelin) administered prior to initiating chemotherapy and then administered 
concurrently with adjuvant chemotherapy protect against ovarian failure and 
reduce the risk of early menopause. In one trial goserelin improved the 
probability of pregnancy from 11% to 21% in patients with hormone  receptor-
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negative early-stage breast cancer. Smaller historical experiences in patients 
with hormone receptor-positive disease have conflicting results with respect to 
the protective effects of GnRH agonists in fertility preservation. 
Patients should be informed of all the various modalities available to 
minimize gonadal damage and preserve ovarian function and future fertility. 
The fertility specialist should discuss specifics of fertility preservation options 
inclusive of types of hormonal interventions and risk involved with ovarian 
stimulation, embryo or oocyte cryopreservation, and other investigational 
options, as well as the probability of successful gestation and childbirth. 
Combining the various modalities for a specific patient may increase the 
odds of preservation of future fertility.it is important for fetal safety that women 
actively avoid becoming pregnant during breast cancer treatment. 
Additional workup 
The panel has re-iterated that routine systemic imaging is not indicated 
for patients with early breast cancer in the absence of signs/symptoms of 
metastatic disease. These recommendations are based on studies showing no 
additional value of these tests in patients with early-stage disease.  
For patients presenting with disease confined to the breast (stage I to II) the 
NCCN panel does not recommend routine systemic imaging in the absence of 
signs or symptoms suspicious for metastatic disease. According to the panel, 
additional tests may be considered in patients who present with locally 
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advanced (T3 N1-3 M0) disease and in those with signs or symptoms suspicious 
for metastatic disease. 
CBCs and LFTs may be considered if the patient is a candidate for preoperative 
systemic therapy, or if otherwise clinically indicated. Additional tests may be 
considered only based on the signs and symptoms. 
A chest diagnostic CT is indicated only if pulmonary symptoms (i.e., cough or 
hemoptysis) are present. Likewise, abdominal imaging using diagnostic CT or 
MRI is indicated if the patient has elevated alkaline phosphatase, abnormal 
results on LFTs, abdominal symptoms, or abnormal physical examination of the 
abdomen or pelvis. 
A bone scan is indicated in patients presenting with localized bone pain or 
elevated alkaline phosphatase. The use of PET or PET/CT scanning is not 
indicated in the staging of clinical stage I, II, or operable III (T3 N1) breast 
cancer. The recommendation against the use of PET scanning is supported by 
the high false-negative  rate in the detection of lesions that are small(<1 cm) 
and/or low grade, the low sensitivity for detection of axillary nodal metastases, 
the low prior probability of these patients having detectable metastatic disease, 
and the high rate of false-positive scans. 
FDG PET/CT is most helpful in situations where standard staging studies are 
equivocal or suspicious, especially in the setting of locally advanced or 
metastatic disease. 
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STAGING  
All patients with breast cancer should be assigned a clinical stage of 
disease, and, if appropriate evaluation is available, a pathological stage of 
disease. The routine use of staging allows for efficient identification of local 
treatment options, assists in identifying systemic treatment options, allows for 
the comparison of outcome results across institutions and clinical trials, and 
provides baseline prognostic information. Effective January 2010, the AJCC 
implemented a revision of 7th edition of the AJCC cancer staging manual 
containing important changes and additions to TNM staging system for breast 
cancer. This revision differs from the 2003 edition of AJCC staging manual by 
providing more direction relating to specific methods of clinical and pathologic 
tumor measurement; recommending that all invasive cancers should be assigned 
a combined histologic tumor grade using Elston-Ellis modification of the 
Scarff-Bloom-Richardson grading system; providing clarification of 
classification of isolated tumor cells  in axillary lymph node staging; 
subdividing stage I into stage IA and IB based upon the presence or absence of 
nodal micro metastasis (N0 versus N0mi+); and defining a new category of 
M0(I+) disease referring to tumor cells microscopically detectable in bone 
marrow or circulating blood or found incidentally in other tissues not exceeding 
0.2 mm in patients who have no signs or symptoms of metastasis. This version 
of the AJCC staging manual also recommends the collection of biomarkers such 
as hormone receptor status (estrogen receptor ER and progestron receptor PR) 
49 
 
and human epidermal growth factor receptor 2 HER2 status, although these 
characteristics do not specifically influence assigned stage of disease. 
T STAGING 
The T classification of the primary tumor is the same regardless of 
whether it is based on clinical or pathologic criteria, or both. Size should be 
measured to the nearest millimeter. If the tumor size is slightly less than or 
greater than a cut off for a given T classification, it is recommended that the size 
be rounded to the millimeter reading that is closest to the cutoff. For example, a 
reported size of 1.1 mm is reported as 1 mm, or a size of 2.01 cm is reported as 
2.0 cm. Designation should be made with the subscript “c” or “p” modifier to 
indicate whether the T classification was determined by clinical (physical 
examination or radiologic) or pathologic measurements, respectively. In 
general, pathologic determination should take precedence over clinical 
determination of T size. 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ 
Tis  (DCIS) Ductal carcinoma in situ 
Tis  (LCIS) Lobular carcinoma in situ 
Tis  (Paget’s) Paget’s disease of the nipple NOT associated with invasive 
carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in the underlying 
breast parenchyma. Carcinomas in the breast parenchyma associated with 
50 
 
Paget’s disease are categorized based on the size and characteristics of the 
parenchymal disease, although the presence of Paget’s disease should still be 
noted 
T1  Tumor ≤20 mm in greatest dimension 
T1mi  Tumor ≤1 mm in greatest dimension 
T1a  Tumor >1 mm but ≤5 mm in greatest dimension 
T1b  Tumor >5 mm but ≤10 mm in greatest dimension 
T1c  Tumor >10 mm but ≤20 mm in greatest dimension 
T2  Tumor >20 mm but ≤5 cm in greatest dimension 
T3  Tumor >50 mm in greatest dimension 
T4  Tumor of any size with direct extension to the chest wall and/or to the 
skin (ulceration or skin nodules)* 
T4a  Extension to chest wall, not including only pectoralis muscle 
adherence/invasion 
T4b  Ulceration and/or ipsilateral satellite nodules and/or edema (including 
peaud’orange) of the skin, which do not meet the criteria for inflammatory 
carcinoma 
T4c  Both T4a and T4b 
T4d  Inflammatory carcinoma** 
*Note: Invasion of the dermis alone does not qualify as T4 
**Note: Inflammatory carcinoma is restricted to cases with typical skin changes 
involving a third or more of the skin of the breast. While the histologic presence 
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of invasive carcinoma invading dermal lymphatics is supportive of the 
diagnosis, it is not required, nor is dermal lymphatic invasion without typical 
clinical findings sufficient for a diagnosis of inflammatory breast cancer. 
 
Regional lymph nodes — Clinical(N) 
NX  Regional lymph nodes cannot be assessed (e.g., previously removed) 
N0  No regional lymph node metastases 
N1  Metastases to movable ipsilateral level I, II axillary lymph node(s) 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are clinically 
fixed or matted; or in clinically detected* ipsilateral internal mammary nodes in 
the absence of clinically evident axillary lymph node metastases 
N2a  Metastases in ipsilateral level I, II axillary lymph nodes fixed to one 
another (matted) or to other structures 
N2b  Metastases only in clinically detected* ipsilateral internal mammary 
nodes and in the absence of clinically evident level I, II axillary lymph node 
metastases 
N3  Metastasis in ipsilateral infraclavicular (level III axillary) lymph node(s) 
with or without level I, II axillary lymph node involvement; or in clinically 
detected* ipsilateral internal mammary lymph node(s) with clinically evident 
level I, II axillary lymph node metastases; or metastases in ipsilateral 
supraclavicular lymph node(s) with or without axillary or internal mammary 
lymph node involvement 
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N3a  Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b  Metastasis in ipsilateral internal mammary lymph nodes(s) and axillary 
lymph node(s) 
N3c  Metastasis in ipsilateral supraclavicular lymph node(s) 
 
*Notes: “Clinically detected” is defined as detected by imaging studies 
(excluding lymphoscintigraphy) or by clinical examination and having 
characteristics highly suspicious for malignancy or a presumed pathologic 
macrometastasis based on fine needle aspiration biopsy with cytologic 
examination. Confirmation of clinically detected metastatic disease by fine 
needle aspiration without excision biopsy is designated with an (f) suffix, e.g., 
cN3a(f). Excisional biopsy of a lymph node or biopsy of a sentinel node, in the 
absence of assignment of a pT, is classified as a clinical N, e.g., cN1. 
Information regarding the confirmation of the nodal status will be designated in 
site-specific factors as clinical, fine needle aspiration, core biopsy, or sentinel 
lymph node biopsy. Pathologic classification (pN) is used for excision or 
sentinel lymph node biopsy only in conjunction with a pathologic T assignment. 
Regional lymph nodes—Pathologic (pN) 
pNX  Regional lymph nodes cannot be assessed (e.g., previously removed, or 
not removed for pathologic study) 
pN0b  No regional lymph node metastasis identified histologically 
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Note: Isolated tumor cell clusters (ITC) are defined as small clusters of cells not 
greater than 0.2 mm, or single tumor cells, or a cluster of fewer than 200 cells in 
a single histologic cross-section. ITCs may be detected by routine histology or 
by immunohistochemical (IHC) methods. Nodes containing only ITCs are 
excluded from the total positive node count for purposes of N classification but 
should be included in the total number of nodes evaluated. 
pN0(i-)  No regional lymph node metastasis histologically, negative IHC 
pN0(i+)  Malignant cells in regional lymph node(s) no greater than 0.2 mm 
(detected by H&E or IHC including ITC) 
pN0(mol-)  No regional lymph node metastasis histologically, negative 
molecular findings [reverse-transcriptase polymerase chain reaction (RT-PCR)] 
pN0(mol+)  Positive molecular findings (RT-PCR)**, but no regional lymph 
node metastases detected by histology or IHC  
pN1   Micrometastases; or metastases in 1-3 axillary lymph nodes; and/or 
in internal mammary nodes with metastases detected by sentinel lymph node 
biopsy but not clinically detected*** 
pN1mi  Micrometastases (greater than 0.2 mm and/or more than 200 cells, 
but none greater than 2.0 mm) 
pN1a   Metastases in 1-3 axillary lymph nodes, at least one metastasis 
greater than 2.0 mm 
pN1b   Metastases in internal mammary nodes with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
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detected*** 
pN1c  Metastases in 1-3 axillary lymph nodes and in internal mammary 
lymph nodes with micrometastases or macrometastases detected by sentinel 
lymph node biopsy but not clinically detected 
pN2   Metastases in 4-9 axillary lymph nodes; or in clinically 
apparent*** internal mammary lymph nodes in the absence of axillary lymph 
node metastases 
pN2a   Metastases in 4-9 axillary lymph nodes (at least one tumor deposit 
greater than 2.0 mm) 
pN2b   Metastases in clinically detected*** internal mammary lymph 
nodes in the absence of axillary lymph node metastases pN3Metastases in 10 or 
more axillary lymph nodes; or in infraclavicular (level III axillary) lymph 
nodes; or in clinically detected **** ipsilateral internal mammary lymph nodes 
in the presence of one or more positive level I, II axillary lymph nodes; or in 
more than three axillary lymph nodes and in internal mammary lymph nodes 
with micrometastases or macrometastases detected by sentinel lymph node 
biopsy but not clinically detected***; or in ipsilateral supraclavicular lymph 
nodes 
pN3a   Metastases in 10 or more axillary lymph nodes (at least one tumor 
deposit greater than 2.0 mm); or metastases to the infraclavicular (level III 
axillary lymph) nodes 
pN3b   Metastases in clinically detected**** ipsilateral internal mammary 
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lymph nodes in the presence of one or more positive axillary lymph nodes; or in 
more than three axillary lymph nodes and in internal mammary lymph nodes 
with micrometastases or macrometastases detected by sentinel lymph node 
biopsy but not clinically detected*** 
pN3c   Metastasis in ipsilateral supraclavicular lymph nodes 
* Classification is based on axillary lymph node dissection with or without 
sentinel lymph node biopsy. Classification based solely on sentinel lymph node 
biopsy without subsequent axillary lymph node dissection is 
designated (sn) for “sentinel node,” e.g., pN0(sn).  
** RT-PCR: reverse transcriptase/polymerase chain reaction. 
*** “Not clinically detected” is defined as not detected by imaging studies 
(excluding lymphoscintigraphy) or not detected by clinical examination. 
**** “Clinically detected” is defined as detected by imaging studies (excluding 
lymphoscintigraphy) or by clinical examination and having characteristics 
highly suspicious for malignancy or a presumed pathologic macrometastasis 
based on fine needle aspiration biopsy with cytologic examination. 
 
Distant metastasis (M) 
M0   No clinical or radiographic evidence of distant metastases 
cM0(i+)  No clinical or radiographic evidence of distant metastases, but 
deposits of  molecularly or microscopically detected tumor cells in circulating 
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blood, bone marrow, or other non regional nodal tissue that are no larger than 
0.2 mm in a patient without symptoms or signs of metastases 
M1  Distant detectable metastases as determined by classic clinical and 
radiographic means and/or histologically proven larger than 0.2 mm 
STAGING 
• Stage I T1N0M0 
• Stage IIa T0N1M0 
  T1 N1M0 
  T2N0M0 
IIb T2N1M0 
T3N0M0 
• Stage IIIa T3N1M0 
T0N2M0 
T1 N2M0 
T2N2M0 
T3N2 M0 
  IIIb T4N0M0 
T4N1M0 
T4N2M0 
  IIIc anyT, N3M0 
• Stage IV  anyT, anyN, M1 
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GRADING 
DESCRIPTION STAGE 
Stage 0   In Situ Breast Cancer 
Stage I, IIA, IIB   Early Invasive Breast Cancer  
Stage IIIA or IIIB Advanced LocoRegional Breast Cancer 
Stage IV   Metastatic Breast Cancer  
 
TREATMENT APPROACH 
The treatment of breast cancer includes the treatment of the local disease 
with surgery, radiation therapy, or both and systemic treatment with 
chemotherapy, endocrine therapy, biologic therapy, or combination of these. 
The need for and selection of various local or systemic therapies are based on 
several prognostic and predictive factors. These factors includes tumor 
histology, clinical and pathologic characteristics of primary tumor, Axillary 
lymph node status, tumor hormone receptor (ER/PR), tumor HER2 status, 
mutli-gene testing, presence or absence of detectable metastatic disease, patients 
co morbid conditions, patient age, and menopausal status. 1% of breast cancer 
occurs in men and men with breast cancer should be treated similarly to post 
menopausal woman except that the use of aromatase inhibitors is ineffective 
without concomitant suppression of testicular steroidogenesis. Patient 
preference is a major component of the decision making process, especially in 
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situations in which survival rates equivalent among the available treatment 
options. 
 
Surgical options for stage I and II breast cancer: 
Mastectomy with or without reconstruction. 
Radical mastectomy involves total mastectomy, complete Axillary 
Lymph Node Dissection (ALND) (levels I, II, and III), removal of the pectoralis 
major and minor muscles, and removal of all overlying skin. This surgical 
approach is largely historical and is rarely, if ever, performed in modern 
practice.  
Modified radical mastectomy (MRM) involves total mastectomy and 
ALND. It is indicated for patients with clinically positive lymph nodes or a 
positive axillary node based on previous SLNB or FNAB. 
Total (simple) mastectomy with SLNB is for patients with a clinically 
negative axilla. A skin-sparing mastectomy (preserves skin envelope and 
inframammary ridge) may be performed with immediate reconstruction, 
resulting in improved cosmesis: the nippleareolar complex, a rim of periareolar 
breast skin, and any previous excisional biopsy or partial mastectomy scars are 
excised. 
Immediate reconstruction at the time of mastectomy should be offered to 
eligible patients. Options include latissimus dorsi myocutaneous flaps, 
transverse rectus abdominis myocutaneous flaps, and inflatable tissue expanders 
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followed by exchange for saline or silicone implants. Immediate reconstruction 
has been shown not to affect patient outcome adversely. The detection of 
recurrence is not delayed, and the onset of chemotherapy is not changed. 
Follow-up after mastectomy: physical examination every 3 to 6 months 
for 3 years, then every 6 to 12 months for the next 2 years, and then annually (J 
Clin Oncol. 2006;24:5091). Mammography of the contralateral breast should 
continue yearly. Regular gynecologic follow-up is recommended for all women 
(tamoxifen increases risk of endometrial cancer). 
Breast conservation therapy (BCT): partial mastectomy and SLNB (or 
ALND) followed by breast irradiation. 
Several trials have demonstrated that BCT with adjuvant radiation 
therapy has similar survival and recurrence rates to those for MRM (J Clin 
Oncol. 1992;10:976).  
Contraindications for BCT: not every patient is a candidate for BCT. 
Contraindications include patients who may be unreliable with follow-up or 
radiation therapy (may involve radiation treatment 5 days a week for 5 to 6 
weeks); when the extent of disease prevents adequate negative margins; a high 
tumor-to-breast size ratio, which prevents adequate resection without major 
deformity; persistently positive margins on re-excision partial mastectomy; and 
inability to receive adjuvant radiation (e.g., prior radiation to the chest wall; 
first- and second-trimester pregnancy in which the delay of radiation to the 
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postpartum state is inappropriate; collagen vascular diseases such as 
scleroderma). 
For patients with large tumors who desire BCT, neoadjuvant 
chemotherapy or neoadjuvant hormonal therapy may be offered to attempt to 
reduce the size of the tumor to make BCT attempt possible. 
Partial mastectomy incisions should be planned so that they can be 
incorporated into a mastectomy incision should that prove necessary. Incisions 
for partial mastectomy and either SLNB or ALND should be separate. 
Adjuvant radiotherapy decreases the breast cancer recurrence rate from 
30% to less than 7% at 5 years and is a required component of BCT. 
Follow-up after BCT.  
Physical examinations are the same as those for mastectomy (see earlier 
discussion). A posttreatment mammogram of the treated breast is performed to 
establish a new baseline, no earlier than 6 months after completion of radiation 
therapy. Mammograms are then performed every 6 to 12 months after the new 
baseline mammogram until the surgical changes stabilize and then annually. 
Contralateral breast mammography remains on an annual basis. Regular 
gynecologic follow-up is recommended.[27] 
Management of the axilla.  
Approximately 30% of patients with clinically negative exams will have 
positive lymph nodes in an ALND specimen. The presence and number of 
lymph nodes involved affect staging and thus prognosis. However, 
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complications are not infrequent. Thus, SLNB was developed to provide 
sampling of the lymph nodes without needing an ALND. 
SLNB has been established as a standard of care for predicting axillary 
involvement in most patients with breast cancer. The procedure requires a 
multidisciplinary approach, including nuclear medicine, pathology, and 
radiology. 
 (1)  It involves injection of blue dye (either Lymphazurin or methylene blue) in 
the operating room and/or technetium-labelled sulfur colloid (in the nuclear 
medicine department, radiology suite, or sometimes by the surgeon). The 
combination of blue dye and radioisotope provides higher node identification 
rates and increases the sensitivity of the procedure. The goal is to identify the 
primary draining lymph node(s) in the axillary nodal basin. 
 (2)  A variety of injection techniques are used: intra parenchymal versus 
intradermal (intradermal methylene blue will cause skin necrosis at the injection 
site); peritumoral versus periareolar. 
(3)  The SLN is identified by its blue color, and/or by high activity detected by a 
handheld gamma probe, or by a blue lymphatic seen to enter a non-blue node. 
Palpable nodes are also sentinel nodes, even if not blue or radioactive. 
(4)  Twenty percent to 30% of the time more than one SLN is identified. 
 (5)  Experienced surgeons (those who have performed at least 30 SLNBs, with 
ALND for confirmation) can identify the SLN in greater than 90% of patients, 
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accurately predicting the patients’ remaining axillary lymph node status in 
greater than 97% of cases. 
 (6) If the SLN is positive for metastasis (micrometastasis 0.2 mm or larger, not 
isolated tumor cells ),a standard completion ALND is the current 
recommendation. A recent randomized trial compared the overall survival and 
axillary recurrence rates for patients with limited SLN metastatic disease who 
received breast conservation and systemic therapy and either had ALND versus 
no further axillary procedures. There was no difference in the two groups, 
leading many to defer completion ALND for this subgroup of patients. All 
patients underwent lumpectomy, whole breast radiation, and systemic therapy; 
thus, the results cannot be generalized to all patients with a positive SLN. 
 (7)  Serial sectioning and immune histochemical staining of SLNB specimens 
may improve accuracy in detecting micro metastatic disease. 
 (8)  Currently, isolated tumor cells are considered N0 disease, and therapeutic 
decisions should not be based on finding these. 
Axillary Lymph Node Dissection (ALND).  
Patients with clinically positive lymph nodes should undergo ALND for local 
control. ALND involves the following: 
 (1)  Removal of level I and level II nodes and, if grossly involved, possibly 
level III nodes. Motor and sensory nerves are preserved unless there is direct 
tumor involvement. 
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 (2)  An ALND should remove at least 10 or more nodes. The number of nodes 
identified is often pathologist dependent. 
 (3)  Patients with 4 or more positive lymph nodes should undergo adjuvant 
radiation to the axilla. Selective patients with 1 to 3 positive nodes may also 
benefit from radiation therapy to the axilla. 
(4) Intraoperative complications: potential injury to the axillary vessels and 
neuropathy secondary to injury to the motor nerves of the axilla (the long 
thoracic, thoracodorsal, and medial pectoral nerves). 
 (5)  Most frequent postoperative complications: wound infections and seromas. 
Persistent seroma may be treated with repeated aspirations or reinsertion of a 
drain. Other complications include pain and numbness in the axilla and upper 
arm, impaired shoulder mobility, and lymphedema. Lymphedema occurs in 
approximately 10% to 40% of women undergoing axillary dissection; radiation 
to the axilla increases the risk of this complication. The most effective therapy 
is early intervention with intense physio massage; graded pneumatic 
compression devices and a professionally fitted compression sleeve can also 
provide relief and prevent worsening of lymphedema. Blood draws, blood 
pressure cuffs, and intravenous lines should be avoided in the affected arm, 
mainly to avoid infection in it. Infections of the hand or arm should be treated 
promptly and aggressively with antibiotics and arm elevation because infection 
can damage lymphatics further and cause irreversible lymphedema. 
Lymphedema itself increases the risk of developing angiosarcoma. 
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Adjuvant systemic therapy is given in appropriate patients after completion of 
surgery. 
 1.  All node-positive patients should receive adjuvant chemotherapy. 
Regimens are guided by the tumor biomarkers. Typical regimens comprise four 
to eight cycles of a combination of cyclophosphamide and an anthracycline, 
followed by a taxane administered every 2 to 3 weeks. 
2. Patients with ER-positive tumors receive adjuvant hormonal therapy for 5 
years. Tamoxifen is given to premenopausal women, and aromatase inhibitors 
are given to postmenopausal women (aromatase inhibitors are not used in 
premenopausal women because decreased feedback to the hypothalamus and 
pituitary increases gonadotropin secretion, stimulating the ovary to secrete more 
substrate). 
3. In postmenopausal women older than 70 years, chemotherapy is performed 
less frequently. In postmenopausal women with tumors with ER or PR 
positivity, tamoxifen or an aromatase inhibitor is frequently the sole adjuvant 
medical therapy. 
4. In patients with Her2/neu-positive tumors, polychemotherapy is combined 
with biological therapy targeting theHer2/neu protein: trastuzumab is a 
recombinant monoclonal antibody that binds toHer2/neu receptor to prevent cell 
proliferation. The NSABP trial B-31 and the North Central Cancer Treatment 
Group trial N9831 showed that adding trastuzumab to a chemotherapy regiment 
of doxorubicin, cyclophosphamide, and paclitaxel was associated with an 
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increase in the disease-free survival by 12% and a 33% reduction in the risk of 
death at 3 years. It is usually administered intravenously monthly for 12 months. 
The most serious toxicity with the regiment was cardiac failure (N Engl J Med. 
2005;353:1673). 
 5. Node-negative patients may have increased disease-free survival from 
adjuvant chemotherapy and/or hormonal therapy. An individualized approach is 
crucial and requires thorough discussion with the patient regarding the risks of 
recurrence without adjuvant therapy, the cost and toxicities treatment, and the 
expected benefit in risk reduction and survival. 
Up to 30% of node-negative women die of breast cancer within 10 years if 
treated with surgery alone.  
Node-negative patients who are at high risk and benefit the most from adjuvant 
chemotherapy include those with tumors greater than 1 cm, higher tumor 
grade,Her2/neu expression, aneuploidy, Ki-67 expression, increased percentage 
in S phase, lymphovascular invasion, and ER/PR-negative tumors. 
The NSABP B-20 trial and the International Breast Cancer Study Group 
trial IX showed that polychemotherapy in combination with tamoxifen was 
superior to tamoxifen alone in increasing disease-free and overall survival, 
especially in ER-negative patients, regardless of tumor size. 
The St. Gallen Consensus Panel in 1998 suggested that patients who have 
node-negative disease and whose tumors are 1 cm or less and ER-positive may 
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be spared adjuvant chemotherapy but still may benefi t from adjuvant endocrine 
therapy. 
The Web site http://www.adjuvantonline.com provides an online tool for 
physicians to use to calculate the added benefit of hormonal and 
chemotherapeutic therapies. 
Adjuvant radiation 
 1. Indications for adjuvant radiation to the chest wall and axilla after 
mastectomy include T3 and T4 tumors, attachment to the pectoral fascia, 
positive surgical margins, skin involvement, involved internal mammary nodes, 
inadequate or no axillary dissection, four or more positive lymph nodes, and 
residual tumor on the axillary vein. Presence of one to three positive axillary 
nodes is a relative indication. 
 2.  Randomized, prospective trials have shown a significantly decreased 
recurrence and improved survival in premenopausal women with these 
indications treated with chemotherapy and radiation therapy (N Engl J Med. 
1997;337:949). 
 3.  Adjuvant whole-breast radiationafter BCT decreases the breast cancer 
recurrence rate from 30% to less than 7% at 5 years. 
 4. Complications. Radiation to the chest wall can cause skin changes. 
Infrequent complications include interstitial pneumonitis, spontaneous rib 
fracture, breast fibrosis, pericarditis, pleural effusion, and chest wall myositis. 
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Radiation to the axilla can increase the incidence of lymphedema and axillary 
fibrosis. Angiosarcoma can occur as a late complication. 
 E. Locally advance breast cancer (LABC) comprises T3 or T4, N1 or greater, 
and M0 cancers (stages IIIA and IIIB). 
 1. Staging in LABC. Because of the frequency of distant metastasis at the time 
of presentation, all patients should receive complete blood cell count, complete 
metabolic panel, bone scan, and CT scan of chest and abdomen before 
treatment. 
 2. Non inflammatory LABC (chest wall or skin involvement, skin satellites, 
ulceration, fixed axillary nodes) 
Patients should receive neoadjuvant chemotherapy (often cyclophosphamide 
combined with an anthracycline and taxane), followed by surgery and radiation. 
The high response rates seen with this regimen for stage IIIB allow MRM to be 
carried out, with primary skin closure. Neoadjuvant chemotherapy also provides 
information regarding tumor response to treatment that may aid to guide further 
adjuvant therapy. Adjuvant radiation to the chest wall and regional nodes 
chemotherapy follow surgery; additional adjuvant chemotherapy is also 
necessary in select cases. SLNB may be used in selected patients with a 
clinically negative axilla. 
Patients with stage IIIA disease receiving neoadjuvant chemotherapy who can 
be converted to BCT candidates have no difference in overall survival outcome. 
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Approximately 20% of patients with stage III disease present with distant 
metastases after appropriate staging has been performed. 
 
3.  Inflammatory LABC (T4d) 
This is characterized by erythema, warmth, tenderness, and edema (peau 
d’orange ). It represents 1% to 6% of all breast cancers. An underlying mass is 
present in 70% of cases. Associated axillary adenopathy occurs in 50% of cases. 
It is often misdiagnosed initially as mastitis. Skin punch biopsy confirms the 
diagnosis: in two third of cases, tumor emboli are seen in dermal lymphatics. 
Approximately 30% of patients have distant metastasis at the time of diagnosis. 
Inflammatory breast cancer requires aggressive multimodal therapy because 
median survival is approximately 2 years, with a 5-year survival of only 5%. 
Follow-up.  
Because of higher risk for local and distant recurrence, patients should be 
examined every 3 months by all specialists involved in their care. 
Locoregional recurrence.  
Patients with locoregional recurrence should have a metastatic workup to 
exclude visceral or bony disease and should be considered for systemic 
chemotherapy or hormonal therapy. 
 1. Recurrence in the breast after BCT requires total (simple) mastectomy. 
Provided margins are negative, survival is similar to that for patients who 
received mastectomy initially. 
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 2. Recurrence in the axilla requires surgical resection followed by radiation to 
the axilla and systemic therapy. 
 3. Recurrence in the chest wall after mastectomy occurs in 4% to 5% of 
patients. One third of these patients have distant metastases at the time of 
recurrence, and greater than 50% will have distant disease within 2 years. 
Multimodal therapy is essential. For an isolated local recurrence, excision 
followed by radiotherapy results in excellent local control. Rarely, patients 
require radical chest resection with myocutaneous flap closure. 
 
SURGICAL TECHNIQUE 
 A skin-sparing mastectomy removes all breast tissue, the nipple-areola 
complex, and only 1 cm of skin around excised scars. There is a 
recurrence rate of less than 2% when skin sparing mastectomy is used for 
T1 to T3 cancers.  
 A total (simple) mastectomy removes all breast tissue, the nipple areola 
complex, and necessary skin.  
 An extended simple mastectomy removes all breast tissue, the nipple-
areola complex, necessary skin, and the level I axillary lymph nodes.  
 A modified radical mastectomy removes all breast tissue, the nipple-
areola complex, necessary skin, and the level I and II axillary lymph 
nodes.  
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 The Patey modification of the modified radical mastectomy also removes 
the pectoralis minor muscle, which permits complete dissection of the 
apical (level III) axillary lymph nodes.  
 Scanlon’s operation: Is a modified Patey’s operation wherein instead of 
removing pectoralis minor, it is incised to approach the affected level III 
lymph nodes. 
 Auchincloss modified radical mastectomy: Here pectoralis minor muscle 
is left intact and retracted to dissect level III lymph nodes—commonly 
done now. 
 The Halstead radical mastectomy removes all breast tissue, the nipple 
areolar complex, necessary skin, the pectoralis major and pectoralis 
minor muscles, and the level I, II, and III axillary lymph nodes.  
 
Currently, chemotherapy, hormone therapy, and radiation therapy for 
breast cancer have nearly eliminated the need for a Halstead radical 
mastectomy.  
 
The patient is positioned on the operating table in the supine position for 
induction of general endotracheal anesthesia. A rolled sheet provides modest 
elevation of the ipsilateral hemithorax and shoulder so that shoulder 
movement is not limited. Positioning the patient at the edge of the operating 
table affords the surgeon and the surgical assistant ample access to the breast 
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and axilla and avoids undue retraction on the pectoralis muscle groups or the 
brachial plexus. The ipsilateral breast, neck, shoulder, and hemithorax are 
prepped down to the operating table and across the midline of the chest. 
Folded towels are used to expose the prepped operative field, which includes 
the shoulder, lower neck, sternum, and upper abdominal musculature. The 
towels are secured in place with towel clips or surgical staples. In addition, 
the ipsilateral axilla, arm, and hand are fully prepared within the operative 
field and the arm is positioned on an arm board that is placed perpendicular 
to the operating field. While alternative methods exist for including the arm 
and hand in the operative field, isolation of the hand and forearm with an 
occlusive cotton dressing (stockinette) is preferred. The stockinette is 
secured in place by applying an elastic or cotton bandage distal to the 
ipsilateral elbow, thereby ensuring free mobility of the ipsilateral elbow, 
arm, and shoulder. 
 
Preparation the patient for MRM 
At the commencement of a modified radical mastectomy, the first 
surgical assistant is positioned over the shoulder of the ipsilateral breast, 
cephalad to the arm board. This position permits the assistant to position the 
arm and shoulder and retract the pectoral muscles appropriately at the time of 
the axillary dissection. In an obese patient with large breasts, a second surgical 
assistant can be positioned on the contralateral side of the operating table to 
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assist with exposure of the axilla during axillary dissection. Positioning of the 
surgical team The elliptical incision of the breast skin incorporates the nipple-
areola complex and skin overlying the breast cancer en bloc with skin margins 
that lie 1 to 2 cm from the cephalad and caudal extents of the cancer. Skin flaps 
are developed using cautery or scalpel and extend to the boundaries of 
dissection for the modified radical mastectomy, which are (a) the anterior 
margin of the latissimus dorsi muscle laterally, (b) the midline of the sternum 
medially, (c) the subclavius muscle superiorly, and (d) the caudal extension of 
the breast, which is 3 to 4 cm inferior to the inframammary fold, inferiorly. The 
skin edges are elevated at a right angle to the chest wall to adequately expose 
the superficial fascia. Skin flaps include the skin and tela subcutanea and vary in 
thickness depending on body habitus. The appropriate dissection plane for skin 
flap elevation is deep to the subcutaneous vasculature and superficial to the 
vessels of the breast parenchyma. The classic Stewart Elliptical Incision The 
surgeon elevates the skin flap with consistent thickness to avoid creation of 
devascularized subcutaneous tissues, which can contribute to wound seroma, 
skin necrosis, and flap retraction. Once the skin flaps are developed, the breast 
parenchyma and pectoralis major fascia are elevated from the underlying 
pectoralis major muscle in a plane parallel with the muscle bundles as they 
course from their medial origin (ribs 2 to 6) to their lateral insertion on the 
humerus.  
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Perforating vessels from the lateral thoracic or anterior intercostal arteries, 
which are end arteries that supply the pectoralis major and minor muscles and 
breast parenchyme, are regularly encountered during elevation of the breast 
parenchyme and pectoralis major fascia. These vessels are individually 
identified and secured with 2-0 or 3-0 nonabsorbable sutures. Elevation of the 
breast parenchyme and pectoralis major fascia is continued laterally until the 
lateral edge of the pectoralis major muscle and the underlying pectoralis minor 
muscle are exposed. The surgeon is aware of the anatomic location of the lateral 
neurovascular bundle in which the medial pectoral nerve (laterally placed with 
origin from the medial cord) courses to innervate the pectoralis major and minor 
muscles. If possible, this nerve is preserved to prevent atrophy of the lateral 
head of the pectoralis major, a significant cosmetic and functional defect. 
Once elevation of the breast parenchyme and pectoralis major muscle fascia 
from the underlying pectoralis major muscle is completed, an incontinuity 
axillary lymph node dissection is performed. Exposure of the pectoralis minor 
muscle and incision of the investing fascia of the axilla. Upward retraction of 
the pectoralis major muscle reveals the underlying pectoralis minor muscle and 
an intervening compartment {Rotter's space), which contains lymph nodes 
{Rotter's nodes). After incision of the investing fascia of the axillary space the 
tendinous portion of the pectoralis minor muscle and underlying structures 
{axillary artery and vein, brachial plexus) are readily identified. Digital 
protection of the brachial plexus for division of the insertion of the pectoralis 
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minor muscle on the coracoid process if needed. All loose areolar and lymphatic 
tissues are swept en bloc with the axillary contents. Dissection commences 
superior to inferior with complete visualization of the anterior and ventral 
aspects of the axillary vein. 
Dissection cranial to the axillary vein is inadvisable, for fear of damage 
the brachial plexus and the infrequent observation of gross nodal tissue cephalic 
to the vein. lnvesting fascial dissection of the vein is best completed with the 
cold scalpel following exposure, ligation, and division of all venous tributaries 
on the anterior and ventral surfaces. Caudal to the vein, loose areolar tissue at 
the junction of the vein with the anterior margin of latissimus is swept 
lnferomedially inclusive of the lateral (axillary) nodal group (level l). Care is 
taken to preserve the neuro vascular thoraco dorsal artery, vein, and nerve in the 
deep & axillary space. The thoracodorsal nerve is traced to its innervation of the 
latissimus dorsi muscle laterally. Lateral and axillary nodal groups are retracted 
inferomedially and anterior to this bundle for dissection en bloc with the 
subclavicular (level 3) group. The superomedial most extent of the dissection is 
the clavipectoral fascia (Halsted's ligament). This level of dissection with this 
technique allows the surgeon to mark with metallic clip or suture, the superior 
most extent of dissection. All loose areolar tissue just inferior to the apical nodal 
group is swept of the chest wall leaving the fascia of the serratus anterior intact.  
With dissection parallel to the long thoracic nerve (respiratory nerve of 
Bell), the deep investing serratus fascia is incised. This nerve is closely applied 
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to the investing fascial compartment of the chest wall and must be dissected in 
its entirety cephalic to caudal, to ensure innervation of the serratus anterior and 
avoidance of the “winged scapula” disability. 
 
Axillary lymph node dissection.  
The loose areolar tissue of the axillary space is  elevated and the investing 
layer of the axillary vein is dissected sharply with dissection continuing to allow 
complete visualization of the anterior and ventral surfaces of the vein, as well as 
ligation and division of intervening venous tributaries. The loose areolar tissue 
at the juncture of the axillary vein with the anterior margin of the latissimus 
dorsi muscle laterally is swept inferomedially to include the lateral group of 
axillary lymph nodes (level I). The thoracodorsal artery and vein, which are 
located deep in the axillary space and are invested with loose areolar tissue and 
the axillary lymph nodes of the lateral and subscapular groups, are preserved. 
The lateral axillary lymph node group is retracted inferomedially and anterior to 
the thoracodorsal neurovascular bundle and dissected en bloc with the 
subscapular group of axillary lymph nodes (level I), which is located medially 
between the thoracodorsal nerve and the lateral chest wall. Dissection then 
proceeds medially with extirpation of the central axillary lymph node groups 
{level II}. The long thoracic nerve (Bell's respiratory nerve), which is constant 
in its location anterior to the subscapularis muscle, and is closely applied to the 
investing fascial compartment of the chest wall is identified and preserved. The 
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axillary contents anterior and medial to the long thoracic nerve are then swept 
infero medially with the dissection specimen. When level III lymphadenopathy 
is present, a Auchincloss modification of the axillary dissection is performed 
which involves retraction of the pectoralis minor muscle. This modification 
provides exposure for dissection of the apical axillary lymphnodes (level III).  
 
COMPLICATIONS 
Anatomic Complications of the Modified Radical Mastectomy 
Vascular Injury   
 The first and second perforating vessels are too large for cautery. 
 They are ligated. 
 The axillary vein, if torn, is repaired. Ligation may cause chronic edema. 
Nerve Injury 
 Intercosto brachial nerve: When cut, circumscribed numbness of the 
medial aspect of the ipsilateral upper arm results. 
 Long thoracic nerve: If cut, a winged scapula deformity results. 
 Medial and lateral thoracic nerves: If cut, the pectoralis muscles atrophy. 
 Thoracodorsal nerve: If cut, internal rotation and abduction of the 
shoulder are weakened. 
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PATHOLOGY ASSESMENT 
 A central component of the treatment of breast cancer is full knowledge 
of extent of the disease and biologic features. These factors contribute to the 
determination of the stage of disease, assist in the estimation of the risk that the 
cancer will recur, and provide information that predicts response to therapy (eg: 
ER, PR, HER2). These factors are determined by examination of excised tissue 
and are provided in a written pathology report. Accurate pathology reporting 
requires communication between the clinician and the pathologist relating to 
relevant patient history, prior breast biopsies, prior irradiation to the chest, 
pregnancy status, characteristics of the abnormality biopsied (eg: palpable, 
mamographically detected micro calcification), clinical state of lymph nodes, 
presence of inflammatory change or other skin abnormality, and any prior 
treatment administered (eg: chemotherapy, radiation therapy). The specimen 
should be oriented for the pathologist, and specific requests for the 
determination of biomarkers should be stated (eg: ER, PR, HER2 status). The 
use of consistent unambiguous standards for reporting is strongly encouraged. 
Data from both national and local surveys show that as many as 50% of the 
pathology reports for breast cancer missing some element critical to patient 
management. Significant omissions include failure to orient and report surgical 
margins and failure to report tumor grade consistently. 
The College of American Pathologists (CAP) has developed pathology 
reporting protocols to promote complete and standardised reporting of 
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malignant specimens. CAP provides a protocol for each disease site. That 
includes cancer case summaries (check lists along with background 
documentation). These check lists form the basis for a synoptic, standardised 
reporting of pathologic findings. Consistent, unambiguous, and complete 
pathology reporting is a corner stone of quality breast cancer care, and the 
NCCN breast cancer panel endorses the use of the CAP protocol for reporting 
the pathologic analysis of all breast cancer specimens. 
 
CAP GUIDELINES for pathology reporting 
SPECIMEN IDENTIFICATION 
The following 4 elements identifying the specimen may be listed separately or 
on 1 line: 
Procedure  
o Excision without image-guided localization 
o Excision with image-guided localization 
o Total mastectomy (including nipple and skin) 
o Other (specify): ____________________________ 
o Not specified 
Lymph Node Sampling (select all that apply) (required only if lymph nodes are 
present in the specimen)  
o Sentinel lymph node(s)  
o Axillary dissection (partial or complete dissection) 
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o Lymph nodes present within the breast specimen  
o Other lymph nodes (eg, supraclavicular or location not identified) 
o Specify location, if provided: _________________________ 
 
 
Specimen Laterality 
o Right 
o Left 
o Not specified 
 
Tumor Site: Invasive Carcinoma  
o Upper outer quadrant 
o Lower outer quadrant 
o Upper inner quadrant 
o Lower inner quadrant 
o Retro Areolar 
o Nipple 
Tumor Size: Size of Largest Invasive Carcinoma  
o Microinvasion only (≤1 mm) 
o Greatest dimension of largest focus of invasion >1 mm: ___ mm  
o Additional dimensions: ___ x ___ mm 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
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o Cannot be determined (explain): __________________________ 
Note: The size of the invasive carcinoma should take into consideration the 
gross findings correlated with the microscopic examination. In some cases, it 
may be helpful to use information about tumor size from imaging studies. If 
multiple foci of invasion are present, the size listed is the size of the largest 
contiguous area of invasion. The size of multiple invasive carcinomas should 
not be added together. The size does not include adjacent ductal carcinoma in 
situ (DCIS). 
If there has been a prior core needle biopsy or incisional biopsy showing a 
larger area of invasion than in the excisional specimen, the largest dimension of 
the invasive carcinoma in the prior specimen should be used for T classification, 
if known. 
If there has been prior neoadjuvant treatment and no invasive carcinoma is 
present, the cancer is classified as yTis if there is residual DCIS  and yPT0 if 
there is no remaining carcinoma. A protocol is not required if no cancer is 
present in the specimen  
Histologic Type  
o Invasive mammary carcinoma of no special type (ductal, not otherwise 
specified) 
o Micro-invasive mammary carcinoma 
o Invasive mammary carcinoma with extensive intraductal component 
o Invasive mammary carcinoma with matrix production 
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o Invasive lobular carcinoma 
o Invasive mammary carcinoma, no special type, with lobular features 
o Invasive lobular carcinoma with pleomorphic features 
o Invasive lobular carcinoma, alveolar variant 
o Invasive carcinoma with ductal and lobular features (“mixed type 
carcinoma”) 
o Mucinous carcinoma 
o Invasive mammary carcinoma with mucinous features 
o Tubular carcinoma 
o Invasive mammary carcinoma with tubular features 
o Invasive mammary carcinoma, tubulo-lobular variant 
o Invasive cribriform carcinoma 
o Invasive mammary carcinoma with cribriform features 
o Invasive micropapillary carcinoma 
o Invasive carcinoma with micropapillary features 
o Invasive mammary carcinoma associated with encysted papillary 
carcinoma 
o Invasive papillary carcinoma 
o Invasive solid papillary carcinoma 
o Encapsulated papillary carcinoma 
o Medullary carcinoma 
o Invasive mammary carcinoma with medullary features 
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o Metaplastic carcinoma 
o Metaplastic carcinoma with squamous features  
o Low grade adenosquamous carcinoma 
o Metaplastic carcinoma with low-grade adenosquamous features  
o Low-grade fibromatosis-like metaplastic carcinoma  
o Metaplastic carcinoma, spindle cell type 
o Metaplastic carcinoma, mixed epithelial and mesenchymal type 
o Invasive carcinoma with metaplastic features 
o Carcinosarcoma 
o Adenoid cystic carcinoma 
o Invasive mammary carcinoma with apocrine features 
o Invasive carcinoma with clear cell (glycogen rich) features 
o Invasive mammary carcinoma with neuroendocrine features 
o Invasive carcinoma, with signet-ring cell features 
o Secretory carcinoma   
o Invasive carcinoma, type cannot be determined 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
o Other(s) (specify): ____________________________ 
Note: The histologic type corresponds to the largest carcinoma.  If there are 
smaller carcinomas of a different type, this information should be included 
under “Additional Pathologic Findings.” 
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Inflammatory carcinoma requires the presence of clinical findings of erythema 
and edema involving at least one-third or more of the skin of the breast (see 
explanation under “Pathologic Staging”). 
Special type carcinomas should consist of at least 90% pure pattern. 
 
Histologic Grade (Nottingham Histologic Score)  
o Glandular (Acinar)/Tubular Differentiation 
o Score 1 (>75% of tumor area forming glandular/tubular structures) 
o Score 2 (10% to 75% of tumor area forming glandular/tubular structures) 
o Score 3 (<10% of tumor area forming glandular/tubular structures) 
o Only microinvasion present (not graded) 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
o Score cannot be determined 
Nuclear Pleomorphism 
o Score 1 (nuclei small with little increase in size in comparison with 
normal breast epithelial cells, regular outlines, uniform nuclear 
chromatin, little variation in size) 
o Score 2 (cells larger than normal with open vesicular nuclei, visible 
nucleoli, and moderate variability in both size and shape) 
o Score 3 (vesicular nuclei, often with prominent nucleoli, exhibiting 
marked variation in size and shape, occasionally with very large and 
bizarre forms) 
84 
 
o Only microinvasion present (not graded) 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
o Score cannot be determined 
  
 
Mitotic Rate 
o Score 1 (≤3 mitoses per mm2)  
o Score 2 (4-7 mitoses per mm2)  
o Score 3 (≥8 mitoses per mm2)  
o Only microinvasion present (not graded) 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
o Score cannot be determined 
o Number of mitoses per 10 high-power fields: ___ 
o Diameter of microscope field: ___ mm 
Overall Grade 
o Grade 1 (scores of 3, 4, or 5)  
o Grade 2 (scores of 6 or 7)  
o Grade 3 (scores of 8 or 9)  
o Only microinvasion present (not graded) 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
o Score cannot be determined 
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Note: The grade corresponds to the largest area of invasion. If there are smaller 
foci of invasion of a different grade, this information should be included under 
“Additional Pathologic Findings.” 
 
 
Tumor Focality (required only if more than 1 focus of invasive carcinoma is 
present)  
o Single focus of invasive carcinoma 
o Multiple foci of invasive carcinoma 
 Number of foci: ____ 
 Sizes of individual foci: ____ 
o No residual invasive carcinoma after presurgical (neoadjuvant) therapy 
o Cannot be determined 
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OBSERVATION AND RESULTS  
This study was conducted in Department of General Surgery, Govt. Stanley 
Medical College, Chennai, for a period of 18 months 
 
The total number of patients enrolled for the study: 32  
 
For all the patients Total Mastectomy with Axillary lymph Node dissection was 
done by giving clearance including Level I, II, III and interpectoral nodes which 
were sent for analysis. The histopathology reports were obtained according to 
CAP protocol and the results were analysed. All the patients enrolled in the 
study were females.  
 
 An average of 13 lymph nodes were examined per case (range: 8−20) 
 Axillary lymph node involvement was found in 56% of the cases (18/32). 
 Of the 18 cases, 83% (n = 15) had involvement of level I/II nodes only, 
and 16% (n = 3) had positive ALN in levels III and, or, interpectoral 
nodes, in addition to level I/II. 
 Involvement of lymph nodes in level III and interpectoral nodes without a 
level I metastasis was not found. 
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left  
59% 
right 
41% 
Side Involvement 
 By the inclusion of level III to a level I/II dissection, two cases (11%) 
were converted from one to three positive nodes (pN1) to ≥4 positive 
nodes (pN2). Involvement of lymph nodes in level III was found in 3 
cases (16%)  
 10/32 cases (31%) had ≥4 positive nodes who required adjuvant therapy 
 Palpability of ALN, pathological tumour size, and lymphovascular 
invasion, were significantly associated with level III involvement and ≥4 
positive nodes 
 There was predominance of left side involvement for carcinoma which 
constitutes 19 patients of 32 enrolled 
 
 
 
 
 
 
 
Of the affected breast the upper outer quadrant involvement is the most 
prevelant owing to 59%, followed by upper inner quadrant 16%, followed by 
retroareolar and lower outer quadrant of 12% each and with no involvement of 
lower inner quadrant. 
SIDE Number of 
patients 
percentage 
RIGHT 13 41% 
LEFT 19 59% 
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RA - retroareolar; LOQ - lower outer quadrant; UIQ - upper inner quadrant; 
UOQ - upper outer quadrant; LIQ - lower inner quadrant. 
The age wise distribution predominates people of age group from 41 to 
50 years which constitutes around 37% followed by 51 to 60 yrs constituting 
35%, followed by 31 to 40 years and 61 to 70 years each of 12.5% and more 
than 70 yrs occupying 3%. This defies that the perimenopausal age group are 
more susceptible with breast cancer 
Age Number Percentage 
31 to 40 yrs 4 12% 
41 to 50 yrs 12 38% 
51 to 60 yrs 11 34% 
>60 yrs 5 16% 
LOQ 
12% 
RA 
13% 
UIQ 
16% 
UOQ 
59% 
Chart Title 
Quadrant 
involved 
number percentage 
RA 4 12% 
LOQ 4 13% 
UIQ 5 16% 
UOQ 19 59% 
LIQ 0 0% 
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By clinical staging most of the patients belongs to stage II B (47%), 
followed by stage III A (28%) and stage II A (25%) but the pathological staging 
of the disease varies after HPE report.  
 
 
  
Of the 8 patients in the clinical stage II A disease all were T2N0 disease, 
post operatively 6 belonged to stage II A itself and 2 were only of stage I with 
average size of the tumor being 1.82, average number of nodes that could be 
dissected from the specimen was 12 nodes and all level of nodes including 
interpectoral nodes were negative for malignancy. This signifies that the clinical 
31 - 40 YRS
41 - 50 YRS
51 - 60 YRS
> 60 YRS
4 
12 
11 
5 
Age Wise Distribution 
0
5
10
15
II A II B III A
Series1 8 15 9
Clinical Stage Wise Distribution Clinical stage Number Percentage 
II a 8 25% 
II b 15 47% 
III a 9 28% 
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size of mass is a little larger than pathological size and breast conservation 
surgery can be a good option for these kind of people with T2N0 disease. 
                        
Of 15 patients in clinical stage II B, 13 being T2N1 disease and two being 
T3N0 disease, post operatively 5 belonged to II A, 5 belonged to II B while 5 
belonged to III A disease.  
 Of the 5 patients with pathologic staging II A all were node negative 
(pT2N0) except for one (pT1N1), whose single level I/II node positive for 
malignancy out of 11 nodes dissected. The other 4 patients all the level of 
lymph nodes were negetive with average number of node dissected being 
11. The average size of tumor was 2.3 
 Of 5 patients belonging to pathologic stage II B, one was negative for all 
levels of lymph nodes while 4 were positive for level I/II lymphnodes 
with negative interpectoral and level III nodes. The average number of 
node positive being 2 out of 10 nodes dissected. The average size of the 
tumor being 3.4 cms 
Pathological 
Stage  
Clinical Stage 
8 
Stage II A 
6 
Stage II A 
2 
Stage I  
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 Of 5 patients of pathologic stage III A with clinical stage II B, all were 
postive for level I/II nodes with an average of 4 nodes positive out of 13 
dissected nodes with negative interpectoral nodes and level III nodes. The 
average size of tumor was 3.5 
 
 
Of 9 patients in clincal stage III A, two were pathologic stage II B and all 
others were III A. the average size of the tumor being 5.3 cms. 
In this group all the patients were positive for level I/II with an average of 
4 nodes out of 14 nodes dissected and two patients were postive for 
interpectoral and 3 patients for level III nodes.  
 
 
 
 
 
 
Pathological Stage  
Clinical Stage 
15 
Stage II B 
5 
Stage II A 
1 
T1N1 
4 
T2N0 
5 
Stage II B 
4 
T2N1 
1 
T3N0 
5 
Stage III A 
1 
T3N1 
4 
T2N2 
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REVIEW OF LITERATURE 
1) Interpectoral nodes in carcinoma of the Breast: Requiem or Resurrection 
Authors (Rajiv Y. Chandawarkar MD, Shashank R. Shinde MD); Journal of 
SurgicalOncology;10.1002/(SICI)1096-9098(199607)62:3<158::AID-
SO2>3.0.CO;2-6 
 Fifty-eight consecutive patients undergoing a modified radical 
mastectomy were subjected to complete dissection and pathological assessment 
of the interpectoral fascia and the group of lymph nodes it contains. The 
dissection was carried out in all patients, irrespective of whether they were 
palpable or not. Interpectoral nodes (IPNs) were anatomically present in 28 
patients (48%) and were completely absent in 30 patients (52%). Ten patients 
were Stage I, 18 were Stage II, and 30 were Stage III. Of the 25% (15/58) of 
patients with microscopic metastasis, only 12/15 had palpable nodes; 66% 
(10/15) of patients had axillary and apical nodes positive. Significantly, two 
patients with negative nodes in the axillary and apical group had metastatic 
Rotter's nodes. Of the 15 patients with positive IPNs, nine had primary tumors 
located within the upper quadrants of the breast, whereas only five had tumors 
in lower quadrants and one had a centrally located tumor. The neurovascular 
bundle to the pectoralis major could be safely preserved in 93% (54/58) of 
patients. The incidence of impalpable nodes with microscopic metastasis and 
the evidence of exclusively metastatic interpectoral nodes with uninvolved 
axillary and apical nodes prompt the following conclusions: (1) interpectoral 
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fascia and nodes should be mandatorily dissected in all patients irrespective of 
the nodes being palpable or not; (2) the dissection is anatomic and is associated 
with almost no additional morbidity; (3) the group of patients with IPNs 
positive and the axillary group negative, would benefit maximally from the IPN 
dissection. Similarly, this dissection in all other groups of patients would enable 
a more accurate staging and selection of therapeutic strategies. © 1996 Wiley-
Liss, Inc. 
2. Variation in axillary node dissection influences the degree of nodal 
involvement in breast cancer patients 
Authors Sanjoy Saha MD, William B. Farrar MD, Donn C. Young PhD, 
John J. Ferrara MD, William E. Burak Jr. M  
The study population consisted of 302 patients with invasive breast 
cancer who underwent complete (level I/II/III) axillary lymph node dissection. 
Assuming that all patients had undergone a level I/II dissection, it was 
determined how frequently a patient's nodal category (0, 1–3, 4–9, >10 positive 
nodes) would have been altered if a level I or level I/II/III dissection were 
performed. 302 patients had undergone a level I/II dissection, performing only 
level I dissection would have resulted in a change in nodal category in 15.9% of 
all patients and 36.1% of patients with positive nodes. The corresponding 
changes for a level I/II/III dissection would have been 4.3% and 9.5%, 
respectively. 
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3) A role of interpectoral (Rotter's) lymph node dissection in modified radical 
mastectomy for breast cancer. (PMID:1448050) Yamasaki N , Kodama H, 
Department of Surgery, Niigata Prefectural Central Hospital, Japan. 
To study the influence of interpectoral lymph node (IPN) dissection on 
the prognosis of patients who underwent modified radical mastectomy, IPN was 
carefully dissected and studied pathologically on 168 cases of our breast cancer 
patients operated with modified radical mastectomy. There were 1.2 lymph 
nodes on an average in the interpectoral region, and they were almost 1-2mm in 
diameter. IPN metastases were found in 10 cases. (Tis: 0%, Stage I: 4.9%, Stage 
II: 5.7%, Stage III: 13%). Tumour’s located in outer quadrant in almost all these 
cases. Positive IPN were found in 6 (16%) of n1 alpha group, 1 (10%) of n1 
beta group, and in 3 (50%) of n2 group. All these 3 cases of n2 died of distant 
metastasis and local recurrence. Two (1.7%) of axillary node (1a, 1b) negative 
patients had micro involvement of cancer only in IPN, and are currently 
disease-free. These data suggest that IPN metastasis may occur even in the early 
breast cancer  patients, and that may be controllable by lymph node excision. 
Therefore, routine and careful dissection of IPN through wide opening of sulcus 
interpectoralis is necessary for modified radical mastectomy and even for breast 
preserving operation. 
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CONCLUSION 
On concluding with the observations and results from our study the key points 
were: 
Variations in the level of axillary node dissection for breast cancer which 
includes the interpectoral and level III nodes can result in significant changes in 
the number of positive axillary nodes stepping up the pathologic nodal status 
from pN1 to pN2. This can potentially bias adjuvant therapy recommendations 
if treatment decisions are based on this prognostic factor.  
Involvement of lymph nodes in level III and interpectoral nodes without a 
level I/II metastasis was not found. Level III axillary dissection is appropriate 
for patients with palpable ALN, to reduce the risk of axillary recurrence and 
provide essential adjuvant therapy. 
Interpectoral nodes were positive in patients with stage III A that 
upstages the nodal status of disease for adjuvant therapy, that emphasize the 
importance of interpectoral node dissection to be included in Modified radical 
mastectomy procedure as a routine.  
Other observations were the patient presents to the doctor with carcinoma 
breast only when it attains stage II, this shows the lack of awareness of 
screening procedures in patients which can pick up stage I disease. On 
observation there was no interconnection between the grade of differentiation 
and the level of nodal metastasis. 
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NODE 
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NODES 
LEVEL 
III 
NODES 
TOTAL DISSECT
ED 
GANDHIMATHY 50/F 252/17 LEFT UPPER OUTER 
QUADRANT 
2 0 IIA 1 0 I A 0.4 GRADE III 0 0 0 0 12 
RAMZAN BEE 38/F 799/17 LEFT UPPER OUTER 
QUADRANT 
2 0 IIA 2 0 II A 2 GRADE II  0 0 0 0 12 
RAMISHA BAI 39/F 7080/16 RIGHT UPPER OUTER 
QUADRANT 
2 0 IIA 2 0 II A 2.5 GRADE II 0 0 0 0 13 
MURUGESHWA
RI 
41/F 1355/17  RIGHT UPPER INNER 
QUADRANT 
2 0 IIA 2 0 II A 2.5 GRADE III 0 0 0 0 15 
ANJALI 45/F 4812/16 LEFT UPPER OUTER 
QUADRANT 
2 0 IIA 2 0 II A 2.5 GRADE II 0 0 0 0 13 
PANAMNA 48/f 4585/17 LEFT LOWER OUTER 
QUADRANT 
2 0 IIA 2 0 II A 3 GRADE III 0 0 0 0 10 
DHANAM 48/F 577/17 LEFT UPPER INNER 
QUADRANT 
2 0 IIA 1 0 II A 0.7 GRADE II 0 0 0 0 11 
JOTHI 67/F 2912/16 LEFT UPPER INNER 
QUADRANT 
2 0 IIA 2 0 II A 1 GRADE II 0 0 0 0 10 
DEVI 35/F 1847/17 RIGHT UPPER OUTER 
QUADRANT 
2 1 IIB 2 0 II A 2 GRADE II 0 0 0 0 12 
PREMILA 36/F 3638/16 LEFT LOWER OUTER 
QUADRANT 
2 1 IIB 2 0 II A 2.5 GRADE II 0 0 0 0 10 
JARINA 50/F 6895/16 RIGHT UPPER OUTER 
QUADRANT 
2 1 IIB 1 1 II A 0.5 GRADE II 1 0 0 1 11 
SHANTHI 60/F 6793/16 LEFT UPPER OUTER 
QUADRANT 
2 1 IIB 2 0 II A 4 GRADE II 0 0 0 0 9 
JENOVAH MARY 60/F 7354/16 RIGHT UPPER OUTER 
QUADRANT 
2 1 IIB 2 0 II A 2.5 GRADE II 0 0 0 0 13 
SARALA 45/F 1266/17 LEFT UPPER INNER 
QUADRANT 
2 1 IIB 2 1a II B 3 GRADE II 3 0 0 3 10 
VIJAYALAKHSMI 53/F 1698/17 LEFT UPPER OUTER 
QUADRANT 
2 1 IIB 2 1a II B 3 GRADE II 3 0 0 3 14 
KANNIAMMAL 55/F 1897/17 LEFT RETRO 
AREOLAR 
2 1 IIB 2 1a II B 3 GRADE II 1 0 0 1 8 
MANGALAM 60/F 7170/16 RIGHT UPPER OUTER 
QUADRANT 
2 1 IIB 2 1a II B 2 GRADE II 1 0 0 1 8 
RUKMANIAMM
AL 
70/F 768/17 RIGHT UPPER OUTER 
QUADRANT 
3 0 IIB 3 0 II B 6 GRADE II 0 0 0 0 11 
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SULTHAN BEEVI 46/F 4574/17 RIGHT UPPER OUTER 
QUADRANT 
3 1 IIIA 3 0 II B 5 GRADE II 0 0 0 0 10 
MALLIGA 55/F 5132/16 LEFT UPPER OUTER 
QUADRANT 
3 1 IIIA 2 1a II B 3.5 GRADE II 4 0 0 4 20 
KAMSALA 45/F 4552/17 LEFT UPPER OUTER 
QUADRANT 
3 0 IIB 3 1a III A 6 GRADE II 2 0 0 2 12 
NAGAMMAL 45/F 7023/16 RIGHT UPPER OUTER 
QUADRANT 
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NAGARATHINA
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50/f 5289/16 LEFT UPPER OUTER 
QUADRANT 
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AMUDHA 51/F 1683/17 RIGHT LOWER OUTER 
QUADRANT 
2 1 IIB 2 2a III A 3 GRADE III 6 0 0 6 15 
SUBHAMMAL 60/F 1648/17 LEFT UPPER OUTER 
QUADRANT 
2 1 IIB 2 2a III A 3 GRADE II 4 0 0 4 14 
YEGAVALI 50/F 941/17 RIGHT UPPER INNER 
QUADRANT 
3 1 IIIA 3 2a III A 6 GRADE II  3 1 1 5 16 
NEELA 54/F 1396/17 RIGHT UPPER OUTER 
QUADRANT 
3 1 IIIA 3 1a III A 6 GRADE III 3 0 0 3 11 
PATCHAIAMMA
L 
55/F 4201/17 LEFT RETRO 
AREOLAR 
3 1 IIIA 2 2a III A 4 GRADE II 4 0 0 4 18 
JAYANTHI 60/F 4150/17 LEFT RETRO 
AREOLAR 
3 1 IIIA 3 1a III A 6 GRADE II 3 0 0 3 13 
RABEKKA 64/F 1155/17 RIGHT UPPER OUTER 
QUADRANT 
3 1 IIIA 3 2a III A 7 GRADE II 5 1 1 5 14 
NEELAVATHY 70/F 4733/17 LEFT LOWER OUTER 
QUADRANT 
3 1 IIIA 3 1a III A 6 GRADE II 3 0 2 5 11 
CHINNAPONNU 80/F 1716/17 LEFT RETRO 
AREOLAR 
3 1 IIIA 2 2a III A 4.5 GRADE II 5 0 0 5 15 
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PROFORMA 
SL. NO : 
NAME :      AGE /SEX:   IP NO:  
ADDRESS  
CONTACT NUMBER:  
DATE OF ADMISSION:     DATE OF DISCHARGE/ DEATH:  
HISTORY OF PRESENTING ILLNESS:  
H/O lump in breast   Onset,site,location 
                      Progression 
                                  Associated symptoms 
            Nipple Discharge 
            Nipple Retraction 
            Trauma,Fever 
H/o abdominal pain,jaundice 
H/o headache,back pain 
H/o Loss of Weight,Loss of Appettite 
PAST HISTORY:  
Whether a known case of DM/hypertension/asthma/TB/epilepsy/cardiac illness  
H/o similar episodes of cancer or lump breast in the past, if any: 
H/o major illness/ hospital admissions, if any: 
H/o drug intake/hormonal manupulation usage,if any: 
 
PERSONAL HISTORY: 
   Age of menarche  Marital status  Consanguinity No.of. Children 
  Breast fed: Yes/No            If Yes,Duration of feed:  Age of menopause: 
 
2 
 
FAMILY HISTORY: 
H/o similar complaints in mother, grandmother, female siblings, if any 
CLINICAL EXAMINATION:  
General examination: (after getting consent, with female attender by side) 
Local Examination:      Breast and Axilla 
        Arm, Chest wall, Supraclavicular fossa/ infraclavicular fossa 
Systemic examination:     CVS, RS, CNS, Abdomen, Spine and Cranium 
PROVISIONAL  DIAGNOSIS: 
Staging: 
Risk factors: 
Comorbid disease: 
INVESTIGATIONS:  
CBC:    RFT:    HIV:   HBsAg: 
Anti-HCV:   Blood Grouping & Typing:   BT/CT: 
Chest X-Ray:   ECG:    
USG Breast/Mammogram:    FNAC/Trucut Biopsy: 
USG ABDOMEN:     CT Thorax/Bone scan 
 
FINAL DIAGNOSIS : 
          Revised staging : 
Histopathological report : 
Grade of differentiation : 
 ER/PR status  : 
 Level I/II node : 
Level III node  : 
Interpectoral node :
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INFORMED CONSENT 
 
DISSERTATION TOPIC: 
“SCRUTINY OF EXTENT OF AXILLARY NODE DISSECTION FOR 
PATIENTS WITH PRIMARY BREAST CANCER” 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
NAME AND ADDRESS OF PATIENT: 
I, _____________________ have been informed about the details of the study in my 
own language. I have completely understood the details of the study.  
I am aware of the possible risks and benefits, while taking part in the study. I 
understand that I can withdraw from the study at any point of time and even then, I will 
continue to receive the medical treatment as usual. 
I understand that I will not get any payment for taking part in this study. 
I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I would 
extend my full co-operation for this study. 
 
Name and Address of the Volunteer:  
Signature/Thumb impression of the Volunteer 
Date: 
Witnesses: 
(Signature, Name & Address) 
Date: 
 
Name and signature of investigator: 
(Dr. Mathews. M) 
